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We hypothesized that bone evolved, in part, to enable bony vertebrates to escape 
danger in the wild. In support of this notion we show here that a bone-derived signal is 
necessary to develop an acute stress response (ASR). Indeed, exposure to various 
types of stressors in mice, rats (rodents) and humans leads to a rapid and selective 
surge of circulating bioactive osteocalcin because stressors favor the uptake by 
osteoblasts of glutamate, which prevents inactivation of osteocalcin prior to its 
secretion. Osteocalcin permits manifestations of the ASR to unfold by signaling in post-
synaptic parasympathetic neurons to inhibit their activity, thereby leaving the 
sympathetic tone unopposed. Osteocalcin is also engaged in a complex cross talk with 
the other principal endocrine regulator of the ASR, the hypothalamic-pituitary-adrenal 
axis. Exogenous osteocalcin stimulates an increase in circulating adrenal steroids and 
Ocn-/- mice born of Ocn-/- mothers exhibit a severe developmental defect in adrenal 
steroidogenesis of corticosterone and aldosterone. Like wild-type animals, 
adrenalectomized rodents and adrenal-insufficient patients can develop an ASR, and 
genetic studies suggest that this is due to their high circulating osteocalcin levels. We 
propose that osteocalcin defines a bony vertebrate specific endocrine mediation of the 
ASR. Together these results demonstrate a role for bone in the physiology of danger.
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CHAPTER I: INTRODUCTION 
 
I. Whole organism physiology 
 
In this thesis, I will try to use whole-organism physiology, the concept that no 
organ is an island and that “more is different”1, to understand the skeleton differently 
than it can be understood in isolation. If there were ever an organ so inert that it could 
be studied in isolation it would be the skeleton, a perception that has been both a 
blessing and a curse for the field. And in all honesty, the study of the skeleton as a part 
of the whole was not premeditated, but instead a natural extension of studying the 
skeleton in isolation. In this introduction, I will chart a course from the molecular study of 
the skeleton in isolation to the use of molecular genetics to study the skeleton as an 
influential citizen of the body.  
II. A working definition of the skeleton 
  
Before any questions can be asked about bone biology, there are a few 
definitions to lay out. The skeleton is an organ characterized by its material properties: 
remarkably solid but also flexible and durable. Instead of being confined to a particular 
location, the skeleton extends throughout the body. It comprises over 200 individual 
components, each radically unique but highly consistent in their morphology and 
anatomical location2. The skeleton surrounds vital organs to protect them from physical 
damage and supports muscle to enable movement, which is essential for survival in the 
wild. The skeleton is made of two tissues: cartilage and bone. Cartilage is an avascular 
2	  
structure, its extracellular matrix (ECM) is made mostly of Type II collagen3. Cartilage is 
located at the ends of skeletal components in the adult skeleton3. Bone, by contrast, is a 
richly vascularized tissue whose ECM is made mostly of Type I collagen4. This ECM is 
mineralized in the form of hydroxyapatite crystals (Ca10(PO4)6(OH)2) that are deposited 
onto collagen4. Populating the skeleton are three principal cell types: chondrocytes in 
cartilage, osteoblasts and osteoclasts in bone4. From here on out we will focus on bone 
since the topic of my graduate work is bone physiology.  
The osteoblast, a cell type of mesenchymal origin produces the ECM and 
choreographs its mineralization5-7. The differentiation of the osteoblast from the 
mesenchymal progenitor is orchestrated by a handful of transcription factors, Sox9, 
Osterix, ATF4 and, chief among them, Runx28. The mineralized ECM generated by 
osteoblasts is subsequently destroyed (resorbed) by osteoclasts a cell type of myelo 
monocytic origin9-12. Osteoclasts use a molecular arsenal to acidify and proteolyse the 
mineralized ECM of bone9-11. The osteoclast is thus a unique cell type in that its sole 
purpose is to destroy the organ it resides in13,14. Osteoblasts and osteoclasts are in a 
constant homeostatic relationship coordinated in large part by Rank and RankL: bone 
resorption is followed and balanced by bone formation13,14. During childhood this 
physiological function is called bone modeling and it is the reason why bony vertebrates 
are able to grow. Without the ability to grow an animal cannot walk, compete effectively 
or live and thus bone modeling is by definition a survival function. During adulthood this 
physiological function is called bone remodeling and it explains how a bone can renew 
its structural integrity throughout life13,14. For most of human history bone remodeling 
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was the only orthopedic surgeon around, therefore it too is a survival function in the 
most literal sense. 
II. Bone from two angles 
 
There are at least two ways to envision the physiology of bone. The first sees 
bone as a structure crucial to support and protection of internal organs but otherwise 
inert. The skeleton and the structural support it provides are an endpoint that is acted on 
by the rest of the body. This view of bone physiology gives rise to the question that has 
driven the field since its inception: What affects bone? Explored using an expanding 
arsenal of biological tools over the past half-century, addressing this question has been 
enormously fertile in elucidating how bone mass increases during childhood and is 
maintained constant during adulthood. These many molecular progresses had 
tremendously important therapeutic implications for the understanding and treatment of 
many bone diseases.  
This one question, what affects bone?, has been reframed many times over, and 
each reframing yields new discoveries as if the mysteries of bone could not be 
exhausted. How does a given skeletal element become precisely patterned during 
embryonic development2? How do the osteoblast and the osteoclast differentiate from 
their respective progenitor cells11,14? What is the identity of those osteoblast and 
osteoclast progenitor cells12,15-18? What transcription factors determine these cell 
differentiation processes19-22? What molecular tools do bone cells use to synthesize, 
mineralize, and then destroy the bone ECM23? How are bone formation and bone 
resorption balanced and regulated24-27? How do hormones, nerves, and blood vessels 
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affect the balance of bone formation and bone resorption28-30? These are questions that 
have rightfully dominated the field of skeletal biology for half a century. 
The second vision of bone, the one I will present in this thesis, sees bone also as 
an essential contributor to whole-organism homeostasis. From this view the skeleton is 
an active, reactive and even proactive participant in maintaining the milieu intérieur. 
This new perspective on bone was born directly from earlier views of bone biology but 
only first proposed in the 21st century31. It poses a fundamentally different question: 
What does bone affect? As before, this new question can be reframed in many ways. 
What other organ systems does the skeleton regulate? What physiologies within those 
organ systems does bone affect? What hormone(s) or other molecular tool(s) does 
bone use to control other organ systems? In what physiological scenarios is bone called 
upon to control those other organs? What neuroendocrine circuits call upon bone to 
control other organs? And many more. Looming behind these questions is another one, 
broader, that I will try to touch upon through my work, which is: Why did evolution invent 
bone? For a lack of a better term I will call this second angle on bone biology, the one I 
work on, non-classical bone biology.  
III. Bone, fertility and energy 
 
As mentioned earlier, perhaps the most unique feature of bone is that, during 
bone (re)modeling, it not only synthesizes a massive amount of mineralized ECM but 
also resorbs that matrix and does both of these on a constant basis13. In other words, 
bone commits suicide all day, every day and in hundreds of locations at a time. No other 
organ contains a cell type, like the osteoclast, whose sole purpose is to destroy its host 
organ. Indeed, while some organs may have impressively high rates of cell turnover, 
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and while others need to negatively select imperfect cells during their development, no 
other organ renews itself via perpetual self-destruction.  
Bone remodeling is not just a curious idiosyncrasy; it is evolutionarily perplexing. 
Producing massive amounts of Type 1 collagen rich ECM and destroying it on a 
constant basis consumes a huge amount of energy. Bone uptakes as much glucose as 
the prototypical glucose storage organ, the liver. Bone also uptakes many times more 
glucose than organs commonly believed to consume large amounts of it, like muscle 
and fat32. Clinical observations also establish how bone (re)modeling and energy 
metabolism are linked.  When children do not eat, i.e., are energy deficient, they 
experience a severe retardation in longitudinal skeletal growth33,34. Adults that do not 
eat, i.e., do not intake energy also loose bone and become hypogonadic. Why would 
bone evolve a method of maintaining itself that is so energetically costly during the large 
part of our history when nutrients were so scarce? And once this energetically costly 
method evolved, how does the organism ensure that energy is properly rationed? How 
does the skeleton report its energy usage to the rest of the organism? How is energy 
consumption by the skeleton regulated? 
Another unique feature of bone (re)modeling is that it is firmly under the control of 
the sex hormones, testosterone and, even more so, estrogen35,36. Experimentally, 
removing testosterone or estrogen is one of the most severe and certainly most widely 
used mouse models of bone loss. Clinically, the onset of menopause and the 
concomitant loss of estrogen is the chief cause of osteoporosis in the modern 
population35,36. Does the fact that reproductive hormones are one of, if not the most 
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potent regulators of bone remodeling suggest that bone in turn might regulate 
reproductive biology? 
 These questions lead to the bone, fertilty and energy hypothesis. The hypothesis 
is that, given the energetic costs of bone (re)modeling, as well as the influence of sex 
hormones on the same, there must be a coordinated regulation, endocrine in nature, of 
bone, energy metabolism and other energetically costly physiological functions, such as 
reproduction. If this hypothesis holds any water then three things should be true. First, 
bone remodeling should be regulated by the neuroendocrine systems responsible for 
fine-tuning energy usage in other organs. Second, and this is where the hypothesis 
breaks rank with classical bone biology, bone should produce a signal, endocrine in 
nature that regulates whole organism energy metabolism. Third, a bone-derived 
endocrine signal should also regulate sexual reproduction. 
The first prediction, that bone might be regulated by energy metabolism 
hormones, wound up being true in multiple ways, though I will draw attention to just 
three, discovered between 2000 and 2019. Leptin, insulin and irisin are all hormones 
that help coordinate systemic energy metabolism. Leptin, secreted by fat, provides a 
satiety signal to the brain37,38. Insulin secreted by the pancreas regulates glucose usage 
in most organs39-43. And irisin, released by muscle, may regulate energy expenditure by 
brown fat44. Each of these hormones through distinct cellular and molecular pathways 
influence bone mass. I will not go into much detail about what cell types, signaling 
cascades and mechanisms within bone each of these energy metabolism hormones 
recruits to regulate bone mass29,45-48. But each hormone acts via a unique pathway: 
leptin through Lepr signaling in the central nervous system (Figure 1.1), insulin through 
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Insr signaling in osteoblasts and Irisin, possibly, through αV integrin in osteoblasts. In 
each case, however, the hormone controls bone mass completely independently of its 
effects on energy metabolism29,45-48. It is also important to note that pharmacological 
dose response studies and analyses of mutants in each of these hormonal signaling 
pathways indicate that these hormones control bone mass just as, or in the case of one, 
more potently than they do energy metabolism29,45-49. The best example is leptin. Mice 
with a partial gain-off-function in Lepr signaling (the l/l mutant mouse) exhibit normal 
body weight, appetite and fertility but a reduced bone mass, indicating that leptin 
controls bone mass even more powerfully than it does parts of energy metabolism49. 
Thus, regulation of bone mass is a critical function of many of the hormones that 





Figure 1.1. Leptin, a metabolic hormone, controls bone mass 
Figure 1.1. Leptin, a metabolic hormone, controls bone mass. Leptin signaling in the brain 
increases the activity of the sympathetic nervous system (SNS). Within bone activated 
sympathetic neurites release norepinephrine which signals on Adrb2 in osteoblasts. Adrenergic 
signaling in osteoblasts favors bone resorption by increasing the expression of RankL the 
primary stimulator of osteoclast differentiation and activity50. Leptin is just one of many 
metabolic hormones that powerfully regulates bone, suggesting an intimate relationship 
between bone and energy metabolism. (Adapted from Karsenty et al., 2012)	  
 
The second and third predictions of this hypothesis are that bone should regulate 
energy metabolism and reproduction, respectively. The fil d’Ariane that made it possible 
to study these questions experimentally was found by serendipity in the early 2000s. 
Osteocalcin is a 46 amino acid protein that was first studied in the 1970s and 1980s for 
three reasons: 1) it is the only protein made exclusively within bone 2) it is the most 
abundant non-collagenous protein embedded in the bone ECM and 3) it is one of 
approximately 10 proteins in the body with a unique post-translational modification 
called a gamma-carboxylation (carboxylation), which was of interest to biochemists at 
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the time51. Gamma carboxyl groups on any protein confer a high affinity for calcium ions 
such as those found in spades in the mineralized ECM of bone52,53. For these reasons it 
was hypothesized in the 1970s that osteocalcin might be the long-sought after 
coordinator of mineralization within bone. It was a disappointing surprise in the 1990s 
when it turned out that bone mineralization in Osteocalcin (Ocn)–null mice (Ocn-/-) was 
completely normal54. What was even more of a surprise was that Ocn-/- mice had 
noticeably larger peritoneal fat pads55. This was a confusing observation. Not only is 
osteocalcin a protein expressed exclusively in bone, it is, to this day, the only known 
protein that is expressed exclusively in bone. How could deleting a protein with such an 
exquisite bone-specific pattern of expression result in a mouse with abnormal fat? 
The simple answer in retrospect is that osteocalcin is a hormone.  But as it 
happened, it took a decade from when the Ocn-/- mouse provoked this question until 
the emergence of this answer55. With the hyper-rationality of hindsight, three hallmarks 
of osteocalcin pointed to its secret identity as a hormone. First, osteocalcin circulates in 
the blood stream at a concentration of ng/ml, a concentration commensurate with most 
other known hormones51. This may seem like a dead giveaway, like Clark Kent thinking 
his identity is safe by putting on a simple pair of glasses. But the fact that osteocalcin 
circulates like a hormone was ignored for very good reason. The species of osteocalcin 
that is circulating is not gamma-carboxylated47,51,56. For most other proteins that are 
carboxylated (Factor IX, Factor X, etc.), if that protein is missing its carboxylation (is 
uncarboxylated) it loses its biological activity52,53. Therefore it was assumed, reasonably 
though incorrectly, that the uncarboxylated osteocalcin in the blood stream was 
biologically irrelevant. I will return to this issue in much more detail below.  
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The second hallmark is that the intracellular processing of osteocalcin obeys the 
laws of classical peptide hormone processing. In the 1950-70s there was an explosion 
of new peptide hormones that were sequenced and characterized57-60. During that era 
of endocrinology, Michel Chretien proposed the ‘prohormone theory’ based on patterns 
that had emerged in the sequences of the new peptide hormones61. This theory argued 
that the vast majority of peptide hormones are produced as prohormone precursors, 
cleaved by a dedicated endoproteolytic enzyme into their active form and then released 
from their endocrine cell of origin62. What was true for the vast majority of peptide 
hormones is also true of osteocalcin (Figure 1.2). Osteocalcin is initially transcribed and 
translated into a 96 amino acid pre-propeptide51,63. The osteocalcin pre-propeptide is 
composed of a signal peptide followed by a propeptide followed by the 46 amino acid 
mature osteocalcin peptide64. The activating cleavage of the osteocalcin propeptide to 
produce mature osteocalcin is, as it happens, performed by furin, the very first 
endoproteolytic enzyme discovered in the peptide hormone field64,65.  
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Figure 1.2. Processing of Osteocalcin 
Figure 1.2. Processing of Osteocalcin. (A) Mature carboxylated human and mouse 
osteocalcin. (B) Osteocalcin is synthesized as a prepropeptide. It is cleave into a propeptide, 
the disulfide bond (S) is formed and then furin, a protein convertase, cleaves the propeptide in 
order to form mature osteocalcin. Then, in most cases, osteocalcin is carboxylated (γ) on 
glutamate (E) amino acids 13, 17 and 20 by γ-Glutamyl carboxylase (GGCX) to form a 
hormonally inactivated osteocalcin with high affinity for mineralize extracellular matrix of bone.  
(Adapted from Zoch et al., 2015) 
 
The third hallmark is one that has already been discussed and indeed at the 
time, in the 1970s, was hiding in plain sight. Osteocalcin is the only protein expressed 
exclusively in bone. Most hormones, from insulin, to parathyroid hormone (PTH), to 
leptin, tend to be among the most cell-specific proteins encoded by the genome. This is 





functional logic. If a hormone is a message then the cell type of origin is the author. 
Though, of course, exceptions exist, in most cases, for the message to be interpreted it 
helps if the hormone is expressed by just a single cell type in the body, and even then, 
only in relevant physiological circumstances. Thus osteocalcin has three cardinal 
hallmarks of a hormone: circulation at a concentration of ng/ml in blood, classical gene 
structure and processing of a prohormone, and expression by just a single cell type in 
the body.  
The bone, fertility and energy hypothesis, the large fat pads of Ocn-/- mice and 
the realization that osteocalcin had classical hallmarks of a hormone eventually led to 
the realization that osteocalcin is a bona fide hormone that favors the production of 
insulin55,66-69. Ocn-/- mice have low circulating insulin levels, and increasing circulating 
osteocalcin levels, either genetically or pharmacologically, increases insulin 
concentration in circulation55,66-69.  Osteocalcin acts directly on beta cells, the pancreatic 
cell type that produces and secretes insulin. Within beta cells osteocalcin signaling has 
three effects: promoting proliferation, increasing the expression of the Insulin gene and 
acutely stimulating the release of insulin within seconds55,66-69. In general, the 
consequence of having low insulin levels and low beta cell numbers is impaired glucose 
uptake and hyperglycemia. This is exactly what is observed in Ocn-/- mice.  In addition 
to these effects on insulin, osteocalcin favors energy expenditure, as measured by 
calories consumed per minute and increased production of adiponectin, a hormone 
produced by fat cells55,66-69. The common theme in these functions is that osteocalcin 
favors both energy uptake and usage and therefore fulfills the second prediction from 
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the bone, fertility and energy hypothesis, namely that bone regulates energy 
metabolism55,66-69. 
	  
Figure 1.3. A coordinated regulation of bone, fertility and energy 
Figure 1.3. A coordinated regulation of bone, fertility and energy. In the Pancreas, 
osteocalcin signaling through Gprc6a stimulates the release of insulin within seconds.  
Osteocalcin signaling through Gprc6a also regulates beta β-cell proliferation in a cyclinD1-
dependent manner during embryonic development and adulthood. Insulin from the pancreas 
signals in return in osteoblasts in order to increase osteocalcin release through bone resoprtion. 
Osteocalcin signaling through Gprc6a also regulates male fertility in leydig cells of the testes by 
increasing the expressing of enzymes required for the synthesis of testosterone.  
	  
In addition to energy metabolism, osteocalcin also favors male fertility (Figure 
1.4). How this aspect of osteocalcin unfolds is surprising given that osteoporosis is 
mostly a disease of post-menopausal women 35,36. Yet, female Ocn-/- mice have normal 
estrogen and fertility. In contrast, male Ocn-/- mice have low testosterone levels, low 
sperm count and less leydig cell mass70. As a result of these cellular and molecular 
defects in the testes, Ocn-/- males produce litters less frequently70.  Conversely, 
treatment with osteocalcin produces the inverse result: higher circulating testosterone 
levels, higher sperm count and more leydig cells mass70. Within leydig cells, the cell 
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type that produces testosterone, osteocalcin favors the expression of StAR, Cyp17, 
Cyp11a and 3β-HSD, the proteins required to transport cholesterol and synthesize it 
into testosterone (Figure 1.4)70.  
	  
Figure 1.4. Osteocalcin favors testicular steroidogenesis 
Figure 1.4. Osteocalcin favors testicular steroidogenesis. Osteocalcin signals on Gprc6a on 
leydig cells in the testes to increase testosterone productions. Gprc6a signals through cAMP 
and CREB in order to increase the expression of several enzymes (Cyp11, 3β-HSD, Cyp17) 
required for the multistep conversion of cholesterol into testosterone. Osteocalcin signaling also 
increases the expression of StAR, which transports cholesterol into the mitochondria, the 
location of steroid production. (Adapted from Karsenty et al., 2013). 
 
Beyond these first two endocrine functions of osteocalcin, the pursuit of the bone, 
fertility and energy hypothesis produced two major mechanistic insights about the 
biology of osteocalcin. The first is the discovery of an osteocalcin receptor70. 
Osteocalcin provokes robust and rapid cAMP accumulation in leydig cells ex vivo, which 
indicated that the osteocalcin receptor in this cell type might be a G protein-coupled 
2. The novel dimension of bone physiology
Bone remodeling occurs throughout life in dozens of location in
the skeleton, which is also one of the organs covering the largest
surface in our body. Both the cellular events it entails and the sur-
face covered by the skeleton suggest that this physiological process
is costly energy-wise. Clinical observations support, fully, this view
of bone (re)modeling. Specifically, the absence of food intake, as in
anorectic children causes a near-total arrest of growth and low
bone mass in adulthood (Legroux-Gerot et al., 2005; Misra and
Klibanski, 2011a,b). Moreover, and unrelated to food intake, it
has been known for a long time that the growth and integrity of
both the female and the male skeleton are influenced by sex
steroid hormones. The biological importance of this regulation is
best exemplified by the fact that gonadal failure triggers bone loss
in both genders and leads to osteoporosis in post-menopausal
women (Riggs et al., 1998; Riggs and Melton, 1986). Taken to-
gether, this view of bone (re)modeling and these clinical observa-
tions suggest that there may be a coordinated regulation of bone
mass or growth, energy metabolism and reproduction (Karsenty,
2006; Karsenty and Ferron, 2012).
Many genetic-based studies have shown that this hypothesis is
true in both rodents and humans. The skeleton secretes at least
two hormones. First, fibroblast growth factor 23 (FGF 23) regulat-
ing mineral metabolism through its control of the phosphate
homeostasis that is intimately linked to bone health (Hori et al.,
2011; Shimizu et al., 2012). Second, an osteoblast-specific secreted
protein, osteocalcin, when undercarboxylated, acts as a multifunc-
tional hormone. Osteocalcin acts on pancreatic b cells to increase
their proliferation and insulin secretion (Karsenty and Ferron,
2012; Karsenty and Oury, 2012; Lee et al., 2007). It also promotes
glucose homeostasis by acting in various tissues, such as muscle,
liver and fat (Karsenty and Ferron, 2012; Karsenty and Oury,
2012; Lee et al., 2007) (Fig. 1).
Subsequently, two groups working independently showed that
mice lacking the insulin receptor in osteoblasts (InsRosb!/!mice)
were glucose intolerant and insulin insensitive when fed on
normal chow; that is, they were a phenocopy of the osteocalcin-
gene-deficient mice (Ferron et al., 2012; Ferron et al., 2010; Fulzele
et al., 2010). Because mice lacking the insulin receptor in skeletal
muscle or white adipose tissue do not display glucose intolerance
when fed a normal diet (Bluher et al., 2002; Bruning et al., 1998),
insulin must act in additional tissues to achieve glucose homeosta-
sis. The fact that bone is such a tissue legitimizes the notion that
this tissue is necessary for glucose homeostasis. In addition,
InsRosb!/!mice had significantly less biologically active
(undercarboxylated) osteocalcin in their sera, revealing that insulin
signaling in osteoblasts is a determinant of osteocalcin bioactivity
(Bluher et al., 2002; Bruning et al., 1998). In a manner that is both
elegant and economical, insulin uses the interplay between osteo-
blasts and osteoclasts for that purpose. Specifically, insulin inhibits
the expression in osteoblasts of the gene encoding osteoprotegerin
(Opg) Ferron et al., 2010, which hampers osteoclast differentiation.
In other words, insulin signaling in osteoblasts favors bone resorp-
tion, a process that occurs at pH 4.5 (Silver et al., 1988). Acidic pH is
the only mechanism known to achieve decarboxylation of proteins
(Poser and Price, 1979), therefore, bone resorption decarboxylates
and activates osteocalcin (Ferron et al., 2010) (Fig. 2). Thus, in a
feed forward loop, insulin signaling in osteoblasts promotes its
own secretion by activating osteocalcin. Furthermore, mice and
humans in which bone resorption is genetically impaired show a
decrease in the undercarboxylated form of osteocalcin, resulting
in glucose intolerance (Ferron et al., 2010) (Fig. 2).
The discovery of the hormonal functions of osteocalcin raised
multiple questions with great biological and medical importance.
Chief among them was to elucidate the signaling events triggered
by this hormone in target cells. A prerequisite to address this ques-
tion was the identification of a specific receptor for osteocalcin. Be-
cause most hormones have several functions, the next question
was whether this was the case for osteocalcin.
3. Osteocalcin favors testosterone production by the Leydig cells
of the testis
The well-known regulation of bone remodeling by gonads
(Khosl and Riggs, 2005; Nakamura et al., 2007; Rigg et al.,
2002; Vanderschueren et al., 2004; Kousteni et al., 2002) suggested
Fig. 1. The skeleton is an endocrine organ. The endocrine regulation of energy
metabolism and male reproduction by the bone is mediated by osteocalcin, an
osteoblast-specific secreted molecule. Osteocalcin regulates energy metabolism by
increasing insulin secretion, favoring pancreatic-b-cell proliferation, and increasing
insulin sensitivity in various tissues. In addition, it promotes male reproductive
function by stimulating testosterone synthesis in Leydig cells.
Fig. 2. Molecular mode of action of osteocalcin in regulating testosterone produc-
tion. Osteocalcin has an unusual mode of activation that relies on the interplay
between two specific bone cells: Osteoblasts and Osteoclasts. The osteoblasts
produce and s cr te an ina tive form of this molecule (carboxylated) that is stored
i the extracellular bone matrix (ECM). The activity of the osteoclasts create
resorption lacunae in the ECM inducing a low PH (4.5) which is necessary and
sufficient to bio-activate osteocalcin by promoting its undercarboxylation. The
mechanism by which osteocalcin is activated is regulated in osteoblasts by insulin
signaling, which inhibi s the expr ssion i osteoblasts of the gene encoding
osteoprotegerin (Opg), which hampers osteoclast differentiation. Following its
binding to Gprc6a expressed in Leydig cells, oste calcin favors cAMP production
that leads to the activation of the transcription factor CREB (cAMP response element
binding). CREB activates the expression of several genes encoding the enzymes that
are necessary for testosterone biosynthesis, such as StAR, Cyp11a, 3b-HSD and
Cyp17. Steroidogenic acute regulatory protein (StAR) is crucial for transport of
cholesterol to mitochondria where biosynthesis of steroids is initiated. Cyp11a
encodes the cholesterol side-chain cleavage enzyme (P450scc) that catalyzes the
first and rate-limiting step, which converts cholesterol to pregnenolone. 3b-HSD
and Cyp17 encode two enzymes required during the conversion of pregnenolone to
testosterone. Testosterone is a sex steroid hormone require for many aspects of
testicular functions, such as germ cell survival and spermatogenesis.
522 G. Karsenty, F. Oury / Molecular and Cellular Endocrinology 382 (2014) 521–526
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receptor (GPCR). Analysis of orphan GPCRs expressed in leydig cells of the testes and 
in beta cells of the pancreas but not in ovaries led to the identification of Gprc6a as a 
receptor that is required for osteocalcin signaling70. Cell specific deletion of Gprc6a in 
leydig cells or beta cells reproduces the respective phenotypes of Ocn-/- mice in each of 
these organs69. More telling were the observations that compound mutants lacking one 
allele of Ocn and one allele of Gprc6a specifically in leydig cells also exhibit impaired 
male fertility70. Similarly, compound mutants lacking one allele of Ocn and one allele of 
Gprc6a specifically in beta cells exhibits impaired insulin production69. This was more 
telling because it indicated that in vivo, osteocalcin is the only ligand that explains how 
this receptor, Gprc6a, controls testosterone and insulin synthesis. The role of Gprc6a in 
controlling male fertility and glucose homeostasis has subsequently been extended to 
humans through the analysis of patients heterozygous for a dominant negative mutation 
in Gprc6a and patients homozygous for a hypomorphic mutation in Gprc6a67,71,72. 
The second mechanistic insight uncovered while exploring the bone, fertility and 
energy hypothesis is that osteocalcin is only hormonally active when it is 
uncarboxylated (Figure 1.5)47,55. As alluded to above, within the osteoblast, osteocalcin 
undergoes a post-translational modification called a gamma carboxylation 
(carboxylation)51. Carboxylation is a rare modification that affects a only a handful of 
other proteins, most famously the clotting factors, Factor IX and Factor X52,53.  
Carboxylation can only occur on glutamate residues and is performed by an enzyme 
called γ-glutamyl carboxylase (GGCX), which is highly expressed in osteoblasts47,52,53.  
Osteocalcin is carboxylated on 3 glutamate residues (amino acids 13, 17 and 20) an 
event that takes place in the endoplasmic reticulum. GGCX requires reduced Vitamin K 
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(VKH2) as a cofactor that it converts into vitamin K epoxide (VKO). The reduced vitamin 
K is recycled from vitamin K epoxide by a second enzyme called vitamin K epoxide 
reductase (VKORC1) that is thus indirectly needed for carboxylation (Figure 1.4). 
Carboxylated glutamate has a high affinity for Ca+2 and Pi ions of which there are an 
abundance in mineralized bone51. As a result, osteocalcin synthesized by osteoblasts, 
most of which is carboxylated, is deposited in the extracellular matrix of bone ECM, 
where it the most abundant non-collageneous protein51.  
	  
Figure 1.5. Bone resorption regulates osteocalcin carboxylation 
Figure 1.5. Bone resorption regulates osteocalcin carboxylation. Prior to this thesis work 
the only known mechanism of osteocalcin release from bone was through bone resorption. 
Osteocalcin is synthesized and carboxylated by GGCX in osteoblasts. To carboxylate GGCX 
requires reduced vitamin K (VKH2), which is produced by the enzyme VKORC1 from vitamin K 
epoxide (VKO). Once synthesized and carboxylated osteocalcin is embedded into the extra 
cellular matrix (ECM) of bone during bone formation. Osteoclasts, during bone resorption, 
disassemble the ECM using proteases and acidification. This not only a) physically releases 
osteocalcin from the ECM but also b) the acidity decarboxylates osteocalcin (GLU-OCN). Only 
GLU-OCN can signal on the known osteocalcin receptors. In this way bone resorption releases 
hormonally active osteocalcin.  There are many ways bone resorption can be activated in such 
a way as to release osteocalcin. One example shown in this cartoon is Insulin signaling in 
osteoblasts, which increases the expression of RankL, the primary stimulator of osteoclast 
differentiation and activity. ESP is a largely bone-specific tyrosine phosphatase that inhibits 
Insulin receptor (InsR) activity in osteoblasts. (Adapted from Mera, Ferron and Mosialou, 2018) 
 
protein (Fig. 2A). In the circulation, OCN exists
in two forms: carboxylated OCN (Gla-Ocn) and
undercarboxylated (Glu13-Ocn or Glu-Ocn).
In vitro and in vivo studies in mice have estab-
lished that γ-carboxylation of OCN, particular-
ly on the first Glu residue (Glu13 in mice and
Glu17 in humans), inhibits OCN endocrine
action on energy metabolism and that under-
carboxylated OCN is the bioactive form of this
hormone (Ferron et al. 2008; Zhou et al. 2013).
For instance, inactivation of GGCX in osteo-
blasts results in increased circulating levels of
undercarboxylated OCN and improved glucose
tolerance in mice (Ferron et al. 2015). A cross-
sectional study in postmenopausal obese wom-
en also showed that the level of OCN carbox-
ylation on its Glu17 residue positively correlates
with insulin resistance and low-grade inflam-
mation (Bonneau et al. 2017), suggesting that
γ-carboxylation of OCN negatively regulates
































































Figure 2. Regulation of osteocalcin (OCN) activity. (A) Once γ-carboxylated and secreted by osteoblasts, OCN is
stored in the bone extracellular matrix in an inactive form. To fulfill its beneficial effects on glucose metabolism,
OCN has to be activated, that is, decarboxylated. This is accomplished through osteoclastic bone resorption that
generates the acid pH necessary for OCN decarboxylation. (B) Insulin signaling in osteoblasts affects OCN
activity by increasing bone resorption through osteoprotegerin (Opg) down-regulation. Because OCN stimulates
insulin secretion, a feedforward loop exists between OCN and insulin activity. Esp, a tyrosine phosphatase,
negatively regulates insulin receptor signaling and decreases OCN activity.
Regulation of Energy Metabolism by Bone-Derived Hormones
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As mentioned above, there are also high concentrations of osteocalcin in blood. 
Unlike what is the case in bone, in blood there is a combination of uncarboxylated 
osteocalcin and carboxylated osteocalcin47,73. The uncarboxylated osteocalcin, lacking 
affinity for the bone ECM conferred by carboxylation, circulates freely47. Treatments of 
wild type (WT) mice and of leydig cells in vitro have demonstrated that only 
uncarboxylated osteocalcin is capable of signaling on its receptor and triggering a 
biological effect55,69,70,74,75. This was confirmed genetically55,69,70,74,75. Mice with Ggcx 
deleted specifically in osteoblasts have exclusively uncarboxylated osteocalcin in 
circulation and represent a model of osteocalcin gain of function in multiple organs56. 
If only uncarboxylated osteocalcin (osteocalcin) is bioactive as a hormone but the 
majority of osteocalcin produced by osteoblasts is carboxylated then there must be a 
molecular system controlling the levels of uncarboxylated osteocalcin in circulation. One 
such system is bone resorption76. This novel function of bone resorption was revealed 
while studying the effects of insulin on bone as part of the bone, fertilty and reproduction 
hypothesis. During bone resorption, osteoclasts form a sealed acidified lacuna with the 
extracellular matrix of bone called the resorption lacuna13,14. To acidify this lacuna 
osteoclasts produce H+ ions using an enzyme, carbonic anhydrase II and transport 
those ions into the lacuna using a proton pump, Tcirg113,14. The acidic conditions of the 
resorption lacuna efficiently decarboxylates the osteocalcin embedded within the 
extracellular matrix of bone47. The liberated uncarboxylated osteocalcin is then free to 
enter general circulation. Biochemical assays demonstrate that the low pH of the lacuna 
very efficiently decarboxylates osteocalcin47. And genetic evidence shows that mice 
18	  
lacking Tcirg1, the acidifying proton pump, in osteoclasts or mice in which osteoclasts 
have been ablated with diphtheria toxin, both fail to acidify the bone resorption lacuna 
and have low circulating osteocalcin levels. As a result both models exhibit the same 
phenotypes as Ocn-/- mice47,77. The role of bone resorption in the carboxylic status of 
circulating osteocalcin would not have been uncovered if it were not for the questions 
provoked by the bone, fertility and energy hypothesis.  During the course of this thesis 
work a novel second system of regulating uncarboxylated osteocalcin was discovered, 
prompted by a new hypothesis, and discussed below.  
IV. A rupture in the plot 
 
Testing the bone, fertility and energy hypothesis revealed a great deal about the 
biology of osteocalcin. Like a rabbit hole, it led down into the functions, receptor and 
regulation of a new hormone from a new endocrine organ. It confirmed experimentally 
the existence of an endocrine loop between three physiologies, skeletal, energetic and 
reproductive, that had not previously been connected (Figure 1.3). But if it were the 
whole truth then the osteocalcin field would have reached its end with glycemic control 
and male reproduction. Instead the continued examination of the animal models built to 
study osteocalcin led to the chance discovery of two completely unexpected functions 
for osteocalcin. These functions could not conceivably be explained by the bone, fertilty 
and energy hypothesis and therefore architected its rupture.  
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Figure 1.6. Ostecalcin regulates cognition, learning and anxiety in the brain 
Figure 1.6. Ostecalcin regulates cognition, learning and anxiety in the brain. Osteocalcin 
made in bone crosses the blood brain barrier and signals in the CA3 region of the hippocampus 
through Gpr158 and increases the expression of BDNF, serotonin, dopamine and 
noradrenaline. In addition osteocalcin binds to neurons in a few other brain regions such as the 
ventral tegmental nucleus (VTA), and the dorsal and median raphe nucleus. In the absence of 
osteocalcin signaling in the brain there is a decrease in contextual fear memory retention, 
spatial learning and an increase in depression and anxiety. In addition to its role in adulthood 
osteocalcin crosses the placenta and is required for the development of the hippocampus. In the 
absence of osteocalcin during embryonic development there are even more severe defects in 
spatial learning than if osteocalcin is only absent post embryonically. (Adapted from Obri et al., 
2018) 
 
The first of the two unexpected functions of osteocalcin is its role in brain 
development and physiology (Figure 1.6).  Routine animal handling led to the 
observation that Ocn-/- mice are noticeably docile. This is true of both male and females 
hence ruling out the possibility that their low testosterone is the cause of docility in Ocn-




Ocn-/- mice to better characterize what stands behind this loosely defined docility. What 
stands behind is a major increase in anxiety, a depression and a severe deficit in spatial 
memory and fear-conditioned memory retention. Molecularly, we only have a vague 
picture of what specifically causes each of these defects but on a broad scale there is a 
decrease in the synthesis of all monoamine neurotransmitters in the brains of Ocn-/- 
mice, as well as an increase in the inhibitory neurotransmitter GABA74. There is also 
decreased production of the neuropeptide BDNF in the hippocampus of Ocn-/- mice. 
Multiple lines of evidence points to osteocalcin crossing the blood-brain-barrier and 
acting directly in the brain. Injection of Osteocalcin into the periphery of Ocn-/- mice 
revealed that Osteocalcin crosses the blood-brain-barrier into multiple areas of the brain 
as efficiently as does leptin. Infusion of osteocalcin directly into the third ventricle of the 
brain largely corrects these behavioral defects arguing that osteocalcin signals directly 
in the brain. In the same vein, binding assays on brain slices revealed that osteocalcin 
bound selectively to certain areas of the brain including the dorsal raphe, the ventral 
tegmental area and the CA3 region of the hippocampus74. Surprisingly, Gprc6a is not 
expressed in any area of the brain and Gprc6a-/- mice do not have any behavioral 
abnormalities despite sharing the same defects in glycemic control and male fertility as 
the Ocn-/- mice74. Instead, in the brain, osteocalcin signals through another GPCR of 
the same family as Gprc6a, Gpr15878,79. Selective deletion of Gpr158 in the brain or 
deletion of one allele of Gpr158 and one allele of Osteocalcin leads to increased anxiety 
and defective learning and memory. These data and many others demonstrated that 
osteocalcin is a peripheral hormone that crosses the blood brain barrier and regulates 
anxiety, learning and memory retention.  
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The second unexpected function of osteocalcin is that it is required for adaptation 
to aerobic exercise (exercise) (Figure 1.7). During exercise osteocalcin levels in the 
blood stream increase two-fold within only a few minutes in mice and humans. What 
functional consequence does this have? Exercise capacity can be measured in mice by 
running them on a treadmill apparatus and recording the time at which they reach 
exhaustion. Ocn-/- mice and mice lacking Gprc6a specifically in myoblasts have a 20-
40% decrease in exercise capacity75. Again, the same is true of mice in which a single 
allele of Gprc6a in myofibers and a single allele of Osteocalcin is deleted. During 
exercise, osteocalcin acts in muscle by increasing the uptake of both glucose and fatty 
acids75. There is also an increase in the catabolism of these two nutrients, as defined by 
a metabolomics analysis performed in muscle after exercise75. As a result of these 
osteocalcin-dependent processes muscle produces more ATP molecules and can 
sustain exercise for longer. 
Osteocalcin also favors the secretion of the cytokine interleukin-6 (IL-6) from 
myoblasts within minutes during exercise80. Upon released, IL-6 signals directly on 
osteoblasts to stimulate bone resorption and thus the release of osteocalcin. If either Il6 
is deleted specifically in myoblasts or IL6ra, the IL-6 coreceptor, is deleted specifically is 
osteoblasts then 1) IL-6 fails to increase in the blood stream during exercise, 2) 
osteocalcin also does not increase in the blood stream during exercise and 3) mice 
have severely decreased exercise capacity80. The requirement of IL6 signalling for the 
surge in osteocalcin during endurance exercise has also been confirmed to exist in 
humans80. This bone-muscle-bone feed forward loop is therefore an indispensable part 
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of the endocrine coordination of the organ systems that must be marshaled during an 
endurance exercise.  
	  
Figure 1.7. Osteocalcin favors exercise capacity 
Figure 1.7. Osteocalcin favors exercise capacity. Osteocalcin doubles in the blood stream 
within minutes during endurance exercise. It signals on Gprc6a in myofibers in muscle in order 
to increase the uptake of glucose and fatty acids as well as their usage in ATP production. As a 
result mice deficient in osteocalcin signaling run less and those with increase osteocalcin levels 
run more than control mice. In addition to its effects on energy production, osteocalcin also 
stimulates the release of IL-6 during exercise. IL6 signals on osteoblasts through a gp130-Il6ra 
complex in order to increase RanKL, bone resorption and thus osteocalcin release from bone 
during exercise. In the absence of Il6 in myofibers, Il6ra in osteoblasts of Gprc6a in myofibers, 





Peter Medawar wrote in 1953 that “endocrine evolution is not the evolution of 
hormones but an evolution of the uses to which they are put”81. It is difficult to come to 
any experimentally definitive conclusion about the evolution of a hormone or its 
functions. But we can certainly evaluate the flaws, or rather limitations, in our 
hypotheses about a hormone. Truth to be told, nothing is more fruitful, than when those 
historically important and even validated hypotheses, come into conflict with 
experimental results.  
The critical functions of osteocalcin in the physiology of memory and exercise 
cannot be explained by the bone, fertility and energy hypothesis that had been the 
engine of the field for over 15 years. If the sole purpose of osteocalcin were to serve as 
a message from bone to the energy metabolism systems then why would it also be 
signaling in areas of the brain completely unrelated to energy metabolism? Why would 
osteocalcin have evolved the ability to signal on an entirely separate receptor, Gpr158, 
to fulfill functions such as memory retention that don’t have anything to do with the high 
energetic cost of bone remodeling? And if osteocalcin were simply a bone-derived 
energy metabolism hormone then why would osteocalcin be irrelevant for energy 
metabolism in muscle at rest, but critical during an extreme endurance exercise? And 
why would osteocalcin regulate these two functions in muscle and brain, just as, or 
perhaps even more potently than it regulates insulin secretion? None of these questions 
can be answered by the bone, fertility and energy hypothesis. And so, in the mid 2010s, 
osteocalcin outgrew its founding hypothesis and a plot hole formed in its experimental 
story. The plot hole brought back old questions: What logic links the many known 
functions of osteocalcin? What additional functions might osteocalcin regulate? What 
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other environmental or physiological circumstances akin to exercise might trigger the 
release of osteocalcin? And the question underlying all the others: why is bone an 
endocrine organ? 
V. The physiology of danger 
	  
A plausible way to address all these questions is to look for a common 
denominator not only within the endocrine functions of bone but also between those 
endocrine functions and their classical counterparts. Through its structural properties 
bone protects internal organs, such as the brain, heart and lungs from damage in 
dangerous situations. Bone in the ossicles of the middle ear mediates hearing, whose 
most basic purpose is to detect danger. Finally, throughout evolution the ambulatory 
function of bone has allowed bony vertebrates to seek food and speedily escape 
danger. Thus, through its classical functions bone serves, in multiple ways, a survival 
purpose.  
The same can be argued about several physiological processes enhanced by 
osteocalcin. Memory is needed for animals living in the wild to remember the location of 
scarce food and abundant predators. To that point, osteocalcin and Gpr158 are both 
required for the retention of contextually conditioned fear. The ability to increase 
exercise capacity is an absolute necessity for animals attempting to escape danger. It is 
no coincidence that many, if not all, of the hormones that increase in response to 
danger, corticosterone and catecholamines, also increase during endurance exercise 
alongside osteocalcin. Male fertility and, perhaps, male behavior is indispensable for the 
long-term survival of any species. But circulating testosterone levels also rise in the 
event of acute danger, though the purpose of this rise remains unknown82. Energy 
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mobilization and expenditure, also regulated by osteocalcin, increases acutely in 
response to environmental danger and is crucial to surviving such an encounter. From 
this vantage point, one could propose an accompanying hypothesis, namely that the 
classical and endocrine functions of bone concur to equip bony vertebrates with a tool 
to escape acute danger. 
The idea that the purpose of bone is to be a tool to escape danger echoes an 
early but, at the time, radically new, explanation for the appearance of bone in 
evolutionary history. In the 1930s a bony vertebrate, called the ostracoderm, was 
discovered that predated jawed cartilaginous fish and was many millions of years older 
than the earliest bony vertebrate discovered up until that point.  Alfred Romer, an 
influential evolutionary biologist, analyzed the structure, histology and habitat of these 
remains, which are the closest he had to the first bone in evolutionary history 83,84. 
Romer asked: What can the earliest known bones tell us about why bone developed in 
the first place? He concluded based on their triple layered, armor-like structure, 
organizations surrounding the internal organs and nervous system and because they 
had poor calcium storage capabilities that their purpose was to be protection from 
predators84. The only predators in the same habitat as the ostracoderms were the 
invertebrate eurypterids, 9-foot-long “marine scorpions”83. Romer argued that, in 
contrast to their later occupation as jawed aggressors, the earliest vertebrates were 
prey and they evolved bone as a mechanism of survival from acute predatory danger.  
The most pressing issue for me as graduate student is whether Romer’s 
conclusions about the original purpose of bone extends to the present purpose of 
bone’s hormone, osteocalcin. And that issue is experimentally testable.  The response 
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to danger in mammals is usually called the acute stress response (ASR). The ASR is an 
evolutionarily conserved physiological process that aims to maintain or restore 
homeostasis in animals facing an immediate danger. The ASR produces, an increase in 
temperature and energy expenditure, higher heart rate, and faster respiration, among 
many other manifestations85,86. The sympathetic nervous system that releases 
catecholamine into peripheral organs is considered to be the ultimate mediator of the 
ASR in vertebrates87. There is also an endocrine component to the ASR. The 
hypothalamic, pituitary, adrenal axis is activated during the ASR, which leads to the 
release of glucocorticoids (corticosterone in mice, cortisol in primates) from the adrenal 
gland88. The first step in the HPA axis is the release of corticotrophin-releasing hormone 
(CRH) from the paraventricular nucleus (PVN) of the hypothalamus into the 
hypophyseal blood vessels, connected to the pituitary gland86,88. CRH signals in the 
pituitary gland, where it stimulates the release of adrenocorticotropic hormone 
(ACTH)86,88. ACTH travels through general circulation to the adrenal glands where it 
stimulates the release of glucocorticoids86,88.  During the ASR when HPA axis is 
activated glucocorticoids levels in circulation skyrocket. The glucocorticoids are the 
canonical stress hormone in their respective species along with the catecholamine 
norepinephrine also released from the adrenal gland. One effect the release of 
glucocorticoids has is to favor the increase of glucose in circulation during an ASR.  
However, while corticosterone and cortisol have been studied as stress hormones since 





Figure 1.8. The acute stress response 
Figure 1.8. The acute stress response. The acute stress response is enacted by two systems. 
The first is the sympathetic nervous system (SNS). Stressors activate preganglionic sympathetic 
neurons in the spinal cord stem. These enervate postganglionic ganglia, which in turn enervate 
target organs that must be regulated during acute stress. These neurons are adrenergic and 
secrete norepinephrine to influence organ biology, such as heart rate and blood pressure. 
During an ASR Preganglionic sympathetic neurons also enervate the medulla of the adrenal 
gland, which secrete epinephrine in to the general circulation. The second is the hypothalamic-
pituitary-axis (HPA). Stress stimulates the release of corticotrophin-releasing hormone (CRH) 
that signals in the pituitary to release adrenocorticotropic hormone (ACTH) that enters 
circulation and stimulates the release of glucocorticoid (corticosterone in mice, cortisol in 
humans) from the cortex of the adrenal gland. Glucocorticoids have functions in many organs. 
During the ASR they favor the increase of circulating glucose but the full extend of their purpose 
in the ASR is still an area of investigation. (Adapted from Ulrich-lai et al., 2009) 
 
During my graduate work I hypothesize that osteocalcin enables survival from 
danger by contributing to the ASR in bony vertebrates. Based on this hypothesis, I 
made and tested two predictions: 1) Circulating osteocalcin should increase in response 
to various stressors such as predator stimuli, pain and perhaps others. The increase in 


















Relating to the first neuron in 
the two-neuron chains that 
mediate autonomic responses.
Postganglionic
Relating to the second neuron 
in the two-neuron chains that 
mediate autonomic responses.
involve reflex arcs that communicate with areas in the 
medulla (for example, the rostral ventrolateral medulla) 
and preganglionic sympathetic neurons in the inter-
mediolateral cell column of the spinal cord1 (FIG. 2). 
Coordinated modulation of the parasympathetic branch 
of the ANS also occurs following stress, to alter the ‘vagal 
tone’ to the heart and lungs1 and to help control the dura-
tion of autonomic responses. This parasympathetic 
response to stress is mediated by the nucleus ambiguus 
and the dorsal motor nucleus of the vagus nerve, possi-
bly through input from the nucleus of the solitary tract 
(NTS)1 (FIG. 2). In addition, medullary and spinal cord 
systems inform higher-order autonomic integrative 
sites in the hindbrain (for example, the raphe pallidus, 
the lateral parabrachial nucleus and the Kölliker-Fuse 
nucleus), midbrain and forebrain (for example, the 
dorsomedial hypothalamus (DMH))1, which modulate 
the autonomic response to stressors in accordance with 
 Box 1 | HPA axis and autonomic nervous system responses to stress
The sympatho-adrenomedullary (see the left-hand side of the figure) and hypothalamic-pituitary-adrenocortical (HPA) 
(see the right-hand side of the figure) axes are the primary systems for maintaining or reinstating homeostasis during 
stress. Stressor exposure results in activation of preganglionic sympathetic neurons in the intermediolateral cell column 
of the thoracolumbar (T and L, respectively) spinal cord (shown in blue). These preganglionic neurons project to pre- or 
paravertebral ganglia that in turn project to end organs and to chromaffin cells of the adrenal medulla. This sympathetic 
activation represents the classic ‘fight or flight’ response that was first characterized by Walter Cannon and colleagues in 
the early twentieth century152; it generally increas s circulating levels of adrenaline (primarily from the adrenal medulla) 
and noradrenaline (primarily from sympathetic nerves), heart rate and force of contraction, peripheral vasoconstriction, and 
energy mobilization. Parasympathetic tone can also be modulated during stress. In the parasympathetic system (shown in 
red), activation of craniosacral preganglionic nuclei activates postganglionic nuclei located in or near the end organs that 
they innervate; parasympathetic actions ar  generally opposite to those of the sympat etic system.
For the HPA axis, stressor exposure activates hypophysiotrophic neurons in the paraventricular nucleus of the 
hypothalamus that secrete releasing hormones, such as corticotropin-releasing hormone (CRH) and arginine vasopressin 
(AVP), into the portal circulation of the median eminence. These releasing hormones act on the anterior pituitary to 
promote the secretion of adrenocorticotropic hormone (ACTH), which in turn acts on the inner adrenal cortex (t at is, the 
zona fasciculata) to initiate the synthesis and release of glucocorticoid hormones (for example, corticosterone in rats and 
cortisol in humans). Circulating glucocorticoids then promote the mobilization of stored energy and potentiate numerous 
sympathetically mediated effects, such as peripheral vasoconstriction. Moreover, the adrenal cortex is directly innervated 
by the sympathetic nervous system, which ca  regulate corticosteroid release153. Thus, t e HPA axis and sympathetic 
system have largely complementary actions throughout the body, including energy mobilization and maintenance of 
blood pressure during stress.
REVIEWS
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osteocalcin in response to these stressors should be tightly controlled by a dedicated 
neuroendocrine loop that is activated during acute stress and stimulates osteocalcin 
release from bone. For this prediction there actually existed a single piece of preliminary 
experimental evidence. In 1995 it was shown in rats that levels of circulating osteocalcin 
double within 10 minutes after a classical acute restraint stress89. What other stressors 
trigger the release of osteocalcin? What neuroendocrine loop regulates the release of 
osteocalcin from bone during an ASR? How does this regulator act on the synthesis, 
processing and/or release of osteoclacin? 2) Osteocalcin should control specific 
manifestations of the ASR in organ systems that are mobilized by it. Is osteocalcin 
required for the mobilization of any organ system during the ASR? What receptors and 
molecular pathways does osteocalcin utilize to contribute to the ASR? During an ASR, 
does osteocalcin act in parallel with, in opposition to or directly through the HPA axis 
and sympathetic nervous system? 
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The endocrine functions of bone raise the question of why an organ viewed as a 
scaffold is also an endocrine organ. A possible answer to this question arises by 
considering bone physiology in an evolutionary context. Through its structural properties 
bone protects internal organs in the event of a trauma and allows animals to move and 
escape danger 84. Bone also mediates hearing, which is a means of detecting danger. A 
similar purpose in the context of danger may be ascribed to several physiological 
processes enhanced by the bone-derived hormone osteocalcin. Memory is needed in 
the wild to recall where food and/or predators are; the ability to increase exercise 
capacity is an absolute necessity for animals attempting to escape danger; and 
circulating testosterone levels rise in the event of danger 75,90-92. From this vantage 
point, one could argue that the classical and endocrine functions of bone concur to 
equip bony vertebrates with a tool to escape danger. If this interpretation is, at least in 
part, correct, bone should regulate other physiological functions activated in the 
presence of danger.  
The acute stress response (ASR) is an evolutionarily conserved physiological 
process that aims to maintain or restore homeostasis in animals facing an immediate 
danger. Such danger produces an increase in temperature and energy expenditure, 
higher heart rate, and faster respiration, among other manifestations 85,86,88. The 
sympathetic nervous system that releases catecholamine into peripheral organs is 
considered to be the ultimate mediator of the ASR in vertebrates86,87. In addition, 
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circulating glucocorticoid hormones surge during an ASR, suggesting that an endocrine 
mediation of the ASR may exist. As steroids, glucocorticoid hormones act mainly, albeit 
not only, at the transcriptional level and need hours to regulate physiological processes 
93, something that seems inconsistent with the need for an immediate response. 
Although this certainly does not rule out that glucocorticoid hormones may be implicated 
in some capacity in the ASR, it suggests the possibility that other hormones, possibly 
peptide ones, could mediate the ASR. This is why, in considering that an original 
purpose of bone was to escape danger, we asked whether bone-derived hormones 
contribute to the ASR in bony vertebrates. 
Addressing the aforementioned question revealed that osteocalcin is necessary 
to develop an ASR. Osteocalcin circulating levels surge within minutes in mice exposed 
to stressors. This effect of stressors on bone is restricted to osteocalcin, independent of 
corticosterone and catecholamine signaling, but requires that osteoblasts take up 
glutamate to enhance the release of bioactive osteocalcin. Osteocalcin is necessary for 
the development of several key manifestations of an ASR by signaling through its 
receptor Gprc6a in post-ganglionic parasympathetic neurons to inhibit cholinergic 
activity. Remarkably, adrenalectomized rodents and patients with adrenal insufficiency 
can still mount a normal ASR. Genetic experiments indicate that this is due to a 
doubling of circulating osteocalcin in these animals. These results identify bone as a 




II. Osteocalcin release during the ASR 
	  
Testing whether any protein made in bone is affected during the acute stress 
response (ASR) revealed that circulating levels of undercarboxylated, i.e., bioactive, 
osteocalcin rose by 50% after a 45-minute-long restraint and by 150% 15 minutes after 
electric foot shocks in 2- to 6-month-old mice, in either sex, in two different genetic 
backgrounds, and at two different times of day (Figures 2.1A-E). Circulating bioactive 
osteocalcin levels also rose in rats after restraint and in humans submitted to a public 
speaking and cross-examination stress that increased heart rate and blood pressure 
89,94 (Figures 2.1F-G). This effect of stressors on bone is restricted to osteocalcin, as 
circulating levels of other bone-derived hormones and synthesis of Type I collagen, the 
most abundant protein of the bone matrix, are unaffected in stressor-exposed mice 
(Figures S2.1A-C). 
As a third stressor we also used 2,4,5-trimethyl thiazoline (TMT), a component of 
fox urine, because it triggers a rapid, innate and centrally controlled fear reaction in the 
mouse 95-98. TMT induced a rise in circulating bioactive osteocalcin that began before 
that of corticosterone, reached its peak at 2.5 minutes and remained steady for at least 
3 hours. In contrast, urine from a non-predator animal used as a negative control did not 
affect circulating bioactive osteocalcin (Figures 2.1H-I). The effect of TMT on circulating 
bioactive osteocalcin prompted us to assess through a chemogenetic designer receptor 
exclusively activated by designer drugs (DREADD) approach 99 whether stressors 
signal in the brain to induce a rise in circulating bioactive osteocalcin.  
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Figure 2.1. Stressors trigger a rapid surge of circulating bioactive osteocalcin 
(Ocn) in rodents and humans 
Figure 2.1. Stressors trigger a rapid surge of circulating bioactive osteocalcin (Ocn) in 
rodents and humans. (A) Serum Ocn levels in 3-month-old WT mice after restraint or foot 
shocks. (B-E) Serum Ocn levels in 2- and 6-month-old, male and female WT mice, at 12 p.m. 
and 8 p.m., and C57Bl/6 or 129SV WT mice after foot shocks. (F) Serum Ocn levels in WT 
female rats after restraint. (G) Serum Ocn levels in WT mice after foot shock and humans after 
public speaking stress. (H) Serum Ocn levels in WT mice after TMT or rabbit urine exposure. (I) 
Serum Ocn and corticosterone levels in TMT-exposed WT mice (gray). (J) Serum Ocn levels 
and rate of Ocn release in TMT-exposed WT mice expressing hM4Di in the BLA after injection 












































































































































































































































±SEM. ns, not significant; *, p<.05; **, p<.01; by Student’s t-test or one-way ANOVA with 
Bonferroni post hoc test. 
 
 Adeno-associated virus (AAV) encoding the inhibitory DREADD hM4Di was injected 
into the baso-lateral amygdala (BLA), a brain region proposed to be a fear center in the 
murine brain, involved in TMT neuronal relays and selectively labeled by viral retrograde 
tracing from the femur 100-106. Subsequent deactivation of the BLA via injection of 
clozapine-N-oxide (CNO), the designer drug, prior to exposure to stressors obliterated 
the surge of osteocalcin in AAV-injected but not in sham-injected mice (Figures 2.1J, 
S2.1D-E). These data indicate that stressors must signal in the BLA to trigger the 
release of bioactive osteocalcin, though they do not exclude the possibility that other 
regions of the brain are also implicated in the development of an ASR.  
III. Osteobasts release osteocalcin in an ASR 
The stressor-induced surge in circulating bioactive osteocalcin levels described 
above occurs independently of sympathetic signaling through β-adrenergic receptors, a 
well-known regulator of osteoblast functions 29; of circulating adrenal steroid hormones 
levels; or of transcriptional events in bones or other tissues (Figures 2.2A-C, S2.2A-D). 
This led us to search for other mechanisms that would account for the release of 




Figure 2.2. Bioactive osteocalcin is released from cells of the osteoblast lineage during 
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Figure 2.2. Bioactive 
osteocalcin is released 
from cells of the 
osteoblast lineage during 
an acute stress response. 
(A) Serum Ocn levels and 
rate of Ocn release in 
nadolol- and vehicle-treated 
WT mice exposed to TMT. 
(B) Serum Ocn levels and 
rate of Ocn release in 
adrenalectomized (ADX) 
and sham-operated TMT-
exposed WT mice. (C) 
Northern blot analysis of 
Ocn (top) and L19 (bottom) 
expression after foot shock. 
(D) Serum Ocn levels and 
rate of Ocn release in oc/oc 
and WT mice before and 
after TMT exposure. (E) 
Serum Ocn levels and rate 
of Ocn release in Tphvil-/- 
and Tphf/f mice before and 
after TMT exposure. (F) 
Serum Ocn levels and rate 
of Ocn release in α1(I) 
CollagenDTA/+ and α1(I) 
Collagen+/+ mice before and 
after TMT exposure. (G) 
Serum Ocn levels and rate 
of Ocn release in 
chlorisondamine- and 
vehicle-treated WT mice 
before and after TMT 
exposure. Mice are 3-
month-old females. Rats are 
4-month-old females. 
Values are mean ±SEM. ns, 
not significant; *, p<.05; **, 
p<.01; by Student’s t-test or 
one-way ANOVA with 
Bonferroni post hoc test. 
	  
35	  
Osteocalcin is activated through decarboxylation, a reaction that occurs in the 
bone resorption lacunae 92. However, circulating bioactive osteocalcin (osteocalcin) 
levels increased equally well in stressor-exposed oc/oc mice that lack functional 
osteoclasts 107 as in control mice (Figure 2.2D). They also increased equally well in 
stressor-exposed WT mice treated with alendronate, an inhibitor of bone resorption 108, 
or with vehicle (Figures S2.2E-F). In agreement with these observations, circulating 
levels of CTX, a biomarker of bone resorption, or of RankL, an activator of bone 
resorption, did not increase within minutes in stressor-exposed WT mice (Figures 
S2.2G-I). In view of these observations we considered the possibility that cells of the 
osteoblast lineage (osteoblasts and osteocytes) that synthesize osteocalcin are the 
ones releasing its bioactive form during an ASR. In support of this notion, we found that 
exposure to stressors increased circulating bioactive osteocalcin even further in 
Tph1villin-/- mice, which have twice as many cells of the osteoblast lineage as in control 
littermates but have normal bone resorption (Figure 2.2E) 109. In contrast, exposure to 
stressors did not increase circulating bioactive osteocalcin in α1(I) CollagenDTA mice, 
which have markedly fewer osteoblasts than WT mice (Figure 2.2F) 110. 
To determine if the release of bioactive osteocalcin is triggered by molecule(s) 
present in the general circulation and that signal in cells of the osteoblast lineage, we 
cultured osteoblasts obtained from WT mice in the presence of sera obtained from 
either unstressed or stressed Osteocalcin-/- (Ocn-/-) mice. In this experimental setting, 
the osteocalcin molecules detected in the supernatant can only originate from the 
cultured osteoblasts. We found that WT osteoblasts produced similar amounts of 
bioactive osteocalcin whether they were cultured in the presence of sera from 
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unstressed or stressed Ocn-/- mice, and none of the specific hormones tested in serum-
free conditions increased the release of bioactive osteocalcin by osteoblasts (Figures 
S2.2J-K). In contrast, blocking neuronal activity with the peripheral ganglionic blocker 
chlorisondamine prevented the increase of circulating bioactive osteocalcin in stressor-
exposed WT mice, thus suggesting a neuronal mediation of the effect of stressors on 
circulating bioactive osteocalcin levels (Figure 2.2G).  
IV. Glutamate regulates osteocalcin carboxylation 
	  
Among all the neurotransmitters tested, only glutamate 111,112 significantly 
increased the amount of bioactive osteocalcin found in the supernatant of mouse 
osteoblasts (Figure 2.3A). In agreement with the data presented in Figure S2.2J, 
circulating glutamate does not change in WT mice exposed to stressors (Figure 2.3B). 
On the other hand, ablating peripheral glutamatergic neurites using a pegylated 
diphtheria toxin that does not cross the blood brain barrier 113 (PEG-DT) injected into 
mice with a conditional diphtheria toxin receptor driven by Vglut2-Cre 114 (Vglut2iDTR 
mice), prevented the stressor-induced increase in circulating bioactive osteocalcin 
(Figures 2.3C, S2.3A-C). In addition, we observed that glutamatergic neurites are 
present in bone and abut osteoblasts 115 (Figure 2.3D). These results suggest that 
glutamate action on cells of the osteoblast lineage can originate from neurites within 
bone. These VGLUT2-positive neurites present in bones are tyrosine hydroxylase (TH) 
negative and do not express any of the markers of sensory neurons tested (Figure 
S2.3D-E). We note that the existence of a subpopulation of VGLUT2-positive, TH-
negative neurons has been previously reported 116-118. 
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Figure 2.3. Glutamate mediates the stressor-induced release of bioactive 
osteocalcin from osteoblasts  
Figure 2.3. Glutamate mediates the stressor-induced release of bioactive osteocalcin 
from osteoblasts. (A) Supernatant Ocn levels after 1-hour treatment of osteoblasts with 
indicated neurotransmitters. (B) Serum glutamate levels before and after TMT exposure. (C) 
Serum Ocn levels and rate of Ocn release before and after TMT stress in pegylated diphtheria 
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metaphysis of WT mice, Ob: osteoblast, N: glutamatergic neurite (scale: 5 µm). (E) Expression 
of glutamate transporters in osteoblasts. (F) Radiolabeled glutamate transport into Glast-/- and 
WT osteoblasts treated with vehicle or UCPH102. (G) Ocn levels in supernatants after 1-hour 
treatment with glutamate and UCPH102 of untreated or warfarin pre-treated mouse osteoblast 
cultures. (H) Supernatant Ocn levels 1 hour after treatment of Glast-/- and WT osteoblasts with 
glutamate. (I) Serum Ocn levels and rate of Ocn release in Glast-/- and WT mice before and 
after TMT exposure. (J) GGCX activity on Ocn in WT osteoblast lysates treated with glutamate. 
(K) Serum Ocn in WT mice expressing hM3Dq in the BLA after injection of CNO or vehicle. 
Mice are 3-month-old females. Values are mean ±SEM. nd, not detectible. ns, not significant; *, 
p<.05; **, p<.01; by Student’s t-test or one-way ANOVA with bonferroni post hoc test. 
 
A single glutamate transporter, Eaat1 or Glast 119,120, is expressed three orders of 
magnitude higher in osteoblasts than any other glutamate transporter and than in any 
other cell type tested, including osteoclasts (Figures 2.3E, S2.3F). The role of glutamate 
transport in osteoblasts through Glast in the release of osteocalcin was delineated in 
several ways. First, incubation with radiolabeled glutamate significantly increased the 
intracellular concentration of glutamate in WT but not Glast-/- osteoblasts; second, 
UCPH102, a specific inhibitor of Glast function 121, prevented the uptake of radiolabeled 
glutamate by WT mouse osteoblasts; third and unlike what is the case in WT 
osteoblasts, glutamate could not stimulate the release of osteocalcin from UCPH102-
treated WT or Glast-/- osteoblasts; fourth and in vivo, circulating bioactive osteocalcin 
did not increase nearly as much in Glast-/- as in WT mice exposed to stressors (Figures 
2.3F-I, S2.3G); and fifth, glutamate prevented the ability of GGCX 122 to carboxylate 
osteocalcin, whereas aspartate, the closest relative to glutamate that is also transported 
by Glast, did not (Figure 2.3J). Accordingly, glutamate could not stimulate the release of 
bioactive osteocalcin from WT osteoblasts treated with warfarin, a potent inhibitor of 
GGCX activity (Figure 2.3G) 123. We should emphasize that the inhibition of osteocalcin 
carboxylation by glutamate was observed at glutamate concentrations similar to or 
below those that have been reported at glutamatergic synapses124. Taken together 
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these data indicate that the entry via Glast of glutamate into cells of the osteoblast 
lineage favors the quick release of bioactive osteocalcin by inhibition of the GGCX 
during an ASR.  
Next we assessed whether signaling in the amygdala affects the release of 
bioactive osteocalcin, used here as a readout of neuronal signaling in bone. For that 
purpose, an AAV encoding the stimulatory DREADD hM3Dq was injected into the baso-
lateral amygdala (BLA). Subsequent activation of the BLA via injection with clozapine-N-
oxide, the designer drug, led to a two-fold increase of circulating bioactive osteocalcin 
(Figures 2.3K, S2.3H). 
V. Osteocalcin is necessary to mount a full ASR   
 
To determine whether the surge of circulating bioactive osteocalcin that is 
observed in stressor-exposed animals contributes to the development of an ASR, we 
studied physiological processes that increase within minutes during an ASR and can be 
reliably monitored in mice. These are: an increase in energy expenditure and circulating 
glucose, a rise in temperature, a faster heart rate, a more efficient respiration as 
measured by arterial spO2, an indicator of respiratory oxygenation of arterial blood if 




Figure 2.4. Osteocalcin signaling in peripheral organs is necessary to mount an 
ASR 
Figure 2.4. Osteocalcin signaling in peripheral organs is necessary to mount an ASR. (A-
F) Energy expenditure, oxygen consumption, temperature, heart rate, arterial oxygen saturation 
and blood glucose in Ocn-/- and WT mice before and after foot shock. (G) Newtonian airway 
resistance in Ocn-/- and WT mice. (H-I) Heart rate and arterial oxygen saturation in Gprc6a-/- 
and WT mice before and after foot shock. (J) Newtonian airway resistance in Gprc6a-/- and WT 
mice. (K-L) Heart rate and arterial oxygen saturation in Gpr158-/- and WT mice before and after 
foot shock. Mice are 3-month-old females. Rats are 4-month-old females. Values are mean 
±SEM. ns, not significant; *, p<.05; **, p<.01; by Student’s t-test or one-way ANOVA with 





































































































































































































Unlike what we observed in WT littermates, Ocn-/- mice experienced only a 
modest increase in energy expenditure, circulating glucose, temperature, heart rate, 
and respiratory oxygenation of arterial blood upon exposure to stressors (Figures 2.4A-
G, S2.4A-B). To determine if osteocalcin signals peripherally and/or centrally to 
enhance these physiological functions during an ASR, we analyzed heart rate and 
oxygenation of arterial blood in mice lacking Gprc6a, a receptor that only mediates 
osteocalcin’s peripheral functions, and in mice lacking Gpr158, a receptor that mediates 
osteocalcin signaling in the brain 125. Both parameters were significantly decreased in 
Gprc6a-/- but not Gpr158-/- mice exposed to stressors (Figures 2.4H-L, S2.4C-
D). Taken together these data indicate that osteocalcin signaling in peripheral organs 
through Gprc6a is necessary for an ASR to unfold. 
VI. Osteocalcin inhibits parasympathetic tone during the ASR 
 
How does osteocalcin signaling in peripheral organs favor the development of 
manifestations of an ASR? To address this question we first explored the relationship 
between osteocalcin and the sympathetic arm of the autonomic nervous system 
because the sympathetic tone is a mediator of the ASR and osteocalcin favors 
catecholamine synthesis in the brain 92. However, we found that circulating 
norepinephrine, its urinary elimination, its content in the lungs, Ucp1 expression in 
brown fat, TH protein content in the heart, accumulation of phospho-CREB (a marker of 
adrenergic signaling) in the heart and expression of various adrenergic receptors in the 
trachea and heart were all similar in Ocn-/- and WT littermates (Figures S2.5A-H). Since 
these markers represent only an indirect measure of the sympathetic tone, we also 
performed direct electrophysiological recordings of sympathetic nerve activity. This 
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study showed no significant change in renal sympathetic tone after intravenous injection 
of osteocalcin (Figure 2.5A). Taken together these data do not provide support for the 
idea that bioactive osteocalcin would regulate the sympathetic tone in peripheral 
organs.  
This led us to test whether it is by inhibiting the parasympathetic tone that 
osteocalcin drives an ASR. In support of this notion, we observed that expression of 
Choline acetyl transferase (Chat), Choline transporter1 (Cht1) and Vesicular 
acetylcholine transporter 1 (Vacht1) that are all needed for acetylcholine (ACH) 
synthesis and recycling 126 was significantly increased in the trachea and heart of Ocn-/- 
and Gprc6a-/- mice, whereas expression of Chat in the brain stem was similar in Ocn-/- 
and WT littermates (Figures 2.5D-E, S2.5I). Conversely, injections of bioactive 
osteocalcin decreased expression of these three genes in the trachea and heart of WT 
mice (Figures S2.5J-K). More directly, intravenous administration of osteocalcin caused 
a rapid and significant decrease in the hepatic parasympathetic nerve activity measured 
in WT mice (Figures 2.5B, S2.5L). Thus, bioactive osteocalcin appears to regulate the 
function of post-ganglionic parasympathetic neurons. The absence of inhibition of the 
parasympathetic tone in Ocn-/- and Gprc6a-/- mice provides an explanation for why 
heart rate variability and circulating levels of gastrin, whose secretion is promoted by the 
parasympathetic tone 127-129, were significantly higher in Ocn-/- and Gprc6a-/- mice than 
in control mice (Figures S2.5M-P). Finally, exposure to TMT caused a marked decrease 
in the hepatic parasympathetic nerve activity in WT mice but could not do so in Ocn-/- 




Figure 2.5. Osteocalcin inhibits parasympathetic tone during an ASR 
Figure 2.5. Osteocalcin inhibits parasympathetic tone during an ASR. (A) Sympathetic 
nerve activity in WT mice injected with Ocn (30 ng/g) or vehicle. (B) Parasympathetic nerve 
activity in WT mice injected with Ocn (30 ng/g) or vehicle. (C) Parasympathetic nerve activity 
after TMT exposure in Ocn-/- and WT littermates. (D-E) Chat, Cht1 and Vacht1 expression in 
trachea and heart of Ocn-/-, Gprc6a-/- and WT littermates. (F) Contraction of electrically 
stimulated Gprc6a-/- or WT mouse tracheal rings treated with Ocn (10 ng/ml) or vehicle. (G) 
Contraction of electrically stimulated human tracheal rings treated with Ocn (10 ng/ml) or 
vehicle. (H-I) Newtonian airway resistance and heart rate in vagotomized or sham-operated 
Ocn-/- and WT mice. (J) Immunofluorescence of airway (scale bar: 15 µm) and cardiac ganglia 
of Gprc6a-Gfp mice, PG: parasympathetic ganglia (scale bar: 12 µm). (K-L) Firing frequency in 























































































































































































































































































































































































treatment with Ocn (15 ng/ml) normalized to control and representative traces of action currents 
in Ocn-/- or vehicle-treated WT tracheal post-ganglionic parasympathetic neurons. (M) Firing 
frequency in tracheal post-ganglionic parasympathetic neurons after treatment with sera from 
stressed Ocn-/- or WT mice. Mice are 3-month-old females. Values are mean ±SEM. ns, not 
significant; *, p<.05; **, p<.01; by Student’s t-test or one-way ANOVA with bonferroni post hoc 
test. 
 
To determine where bioactive osteocalcin signals through Gprc6a to allow 
manifestations of an ASR to develop, and in the absence of a Cre-driver specific to 
post-ganglionic parasympathetic neurons, we performed multiple experiments.  
First, we observed that bioactive osteocalcin directly decreased contraction of 
WT but not Gprc6a-/- tracheal rings within minutes (Figures 2.5F, S2.5Q). This effect 
was dependent on ACH signaling since it was inhibited by atropine, a muscarinic 
receptor inhibitor 130 (Figure S2.5R). Of note, the fact that bioactive osteocalcin 
prevented contraction of human tracheal rings in this assay suggests that osteocalcin 
inhibits the parasympathetic tone in humans as well (Figure 2.5G). Second, bilateral 
cervical vagotomy, a procedure that eliminates parasympathetic signaling to the lungs, 
corrected the bronchoconstriction and slow heart rate in Ocn-/- mice (Figures 2.5H-I). 
Third, and in view of the results presented above, we used mice expressing Green 
fluorescent protein (Gfp) under the control of Gprc6a regulatory elements to determine 
whether this receptor was expressed in post-ganglionic parasympathetic neurons. This 
analysis effectively showed that Gprc6a is expressed in cholinergic post-ganglionic 
parasympathetic neurons in the upper airways and the cardiac ganglia but not 
elsewhere in these organs (Figures 2.5J, S2.5S-T). Fourth, and in the absence of 
mutant mice lacking Gprc6a only in postganglionic parasympathetic neurons, we 
generated WT and Gprc6a-/- mice that express Tomato under the control of the Chat 
promoter to mark parasympathetic neurons (Figure S2.5U). We then isolated 
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parasympathetic neurons from WT or Gprc6a-/- mice and performed patch-clamp 
electrophysiology studies in the presence or absence of osteocalcin. In the conditions of 
this assay, bioactive osteocalcin decreased the frequency of action potentials by more 
than 70% in WT but not in Gprc6a-/- tracheal neurons (Figure 2.5K, 2.5M). Firing 
frequency was restored to normal values 10 minutes after washout (Figure 2.5L).  
Moreover, sera from stressed Ocn-/- mice increased firing of tracheal neurons at least 
30-fold more than sera from stressed WT mice (Figure 2.5M). Taken together these 
results show that a hormone, osteocalcin, inhibits the activity of post-ganglionic 
parasympathetic neurons in the context of an ASR, thus leaving the sympathetic tone 
unabated. 
VII. Osteocalcin and steroid hormone biosynthesis   
	  
There is one obvious aspect of the ASR that we have, so far, overlooked—the 
hypothalamus-pituitary-adrenal (HPA) axis. Indeed, it was so obvious that it was 
overlooked not only in this retelling but also during a large portion of the actual 
execution of this thesis research. In light of the role of osteocalcin in the ASR and that 
glucocorticoids powerfully inhibit the expression of osteocalcin we asked whether 
osteocalcin might regulate steroidogenesis in the adrenal gland. I should mention here 
that this project is still ongoing as I write. 
We found that a single injection of osteocalcin (30 ng/g) increased circulating 
corticosterone levels more than three fold in adult wild-type mice (3 months-old), one 
and 12 and 24 hours after injection (Figure 2.6A). The same was true in rats and non-
human primates (Figure 2.6B-C). Unexpectedly, these single injections of osteocalcin 
also increased, over two fold, in rodents and primates, circulating levels of the 
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mineralocorticoid hormone, aldosterone that is also synthesized in the adrenal cortex 
(Figure 2.6D-F).  
 
Figure 2.6. Osteocalcin stimulates the release of glucocorticoids in mice, rats and 
monkeys 
Figure 2.6. Osteocalcin stimulates the release of glucocorticoids in mice, rats and 
monkeys. (A) Serum corticosterone in WT mice injected with Ocn (30 ng/g) or vehicle. (B) 
Serum corticosterone in WT rats injected with Ocn (30 ng/g) or vehicle. (C) Serum 
corticosterone in Rhesus macaques injected with Ocn (.0135 mg/kg) or vehicle. (D) Serum 
aldosterone in WT mice injected with Ocn (30 ng/g) or vehicle. (E) Serum aldosterone in WT 
rats injected with Ocn (30 ng/g) or vehicle. (F) Serum aldosterone in WT Rhesus macaques 
injected with Ocn (.0135 mg/kg) or vehicle. Mice are 3-month-old females. Rats are 4-month-old 
females. Values are mean ±SEM. ns, not significant; *, p<.05; **, p<.01; by Student’s t-test or 
one-way ANOVA with bonferroni post hoc test. 
 
The impact of a transient increase in circulating osteocalcin levels on adrenal 
steroidogenesis suggested that Ocn-/- mice would present an adrenal insufficiency. 
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Surprisingly, however, whether we look at circulating corticosterone or aldosterone 
levels, blood potassium levels or gland weight, Ocn-/- mice born from Ocn+/- mothers 
(who themselves were also borne of Ocn+/- mothers) were indistinguishable from WT 
littermates (Figure 2.7A-E). Corticosterone was similarly normal in Ocn-/- mice born 
from Ocn+/- mothers 15 minutes following an ASR (Figure 2.7F). How to reconcile these 
negative results with powerful ability of osteocalcin to increase adrenal steroidogenesis? 
To do so we considered that, as it is the case for osteocalcin signaling in the brain, 
maternal osteocalcin may regulate adrenal development and thereby lifelong adrenal 
steroidogenesis. Hence, we analyzed the adrenal phenotype of Ocn-/- mice born from 
Ocn+/- mothers. We observed that circulating corticosterone and aldosterone levels 
were decreased by more than 50% and blood potassium levels were significantly 
elevated in 2 and 3 month-old Ocn-/- mice born from Ocn-/- mothers compared to WT 
mice (Figure 2.7G-I). Remarkably, Crh expression in the hypothalamus and circulating 
ACTH levels were not low in Ocn-/- mice born from Ocn-/- mothers (Data not shown). 
The weight of the adrenal glands in Ocn-/- mice born form Ocn-/- mice was 
approximately 25% lower than that of adrenal glands of WT mice (Figure 2.7J-K). 
Circulating corticosterone was also low during an ASR in Ocn-/- mice born from Ocn-/- 
mothers compared to WT mice (Figure 2.7L).  Taken together these data suggest that 
maternally derived osteocalcin is necessary for adrenal gland development and 
corticosterone and aldosterone levels in adulthood. Additionally these data suggest that 
increased levels of osteocalcin in adulthood might be capable of favoring the output of 
corticosterone and aldosterone in to general circulation. Substantial and ongoing future 
work will be needed in order to understand how and when osteocalcin regulates adrenal 
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steroidgenesis and, more generally, how osteocalcin is a general regulator of steroid 
hormone biosynthesis in two organs, the testes and the adrenal gland. These issues will 
be discussed in the next section of this thesis.  
 
Figure 2.7. Maternal osteocalcin regulates adrenal development 
Figure 2.7. Maternal osteocalcin regulates adrenal development. (A-E) Serum 
corticosterone (A), Serum aldosterone (B), Blood potassium (C), adrenal weight (D, E) in Ocn-/- 
mice from Ocn+/- parents. (F) Serum corticosterone in Ocn-/- mice from Ocn+/- parents before 
and 15 minutes after exposure to TMT. (G-L) Serum corticosterone (G), Serum aldosterone (H), 
Blood potassium (I), adrenal weight (J, K) in Ocn-/- mice from Ocn+/- parents. (L) Serum 
corticosterone in Ocn-/- mice from Ocn-/- parents before and 15 minutes after exposure to TMT. 
Mice are 3-month-old females. Values are mean ±SEM. ns, not significant; *, p<.05; **, p<.01; 
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VIII. Osteocalcin enables adrenalectomized mice to mount an ASR 
	  
The crosstalk between osteocalcin and corticosterone synthesis described above 
begged the question of the respective roles of osteocalcin and corticosterone in the 
development of an full ASR. This was addressed by comparing manifestations of the 
ASR in adrenalectomized (ADX) mice, which lack corticosterone and epinephrine, and 
that were either WT or Osteocalcin deficient.  
As mentioned above, glucocorticoid hormones have been known for decades to 
potently inhibit Osteocalcin expression and production in rodents and humans 131,132. In 
full agreement with this notion, adrenalectomized (ADX) WT mice or rats that have 
undetectable circulating levels of corticosterone have several-fold higher circulating 
bioactive osteocalcin before and after exposure to stressors than sham-operated ones 
(Figures 2.2B, S2.6A). Hence, we reasoned that ADX mice or rats would be useful tools 
to determine whether high circulating bioactive osteocalcin levels might be sufficient to 
allow the development of an ASR in animals lacking both adrenal steroid hormones and 
adrenal-derived catecholamine. 
We found that following exposure to stressors, energy expenditure, temperature, 
heart rate, and respiration increased equally well in ADX and sham-operated WT mice 
(Figures 2.8A-E). Likewise, ADX WT rats that had no circulating corticosterone 
developed an efficient ASR as determined by a rise in body temperature and heart rate 
after restraint (Figures 2.8F-G). ADX mice did have a blunted rise in glucose levels 
during an ASR in comparison to sham-operated mice (Figure S2.6B). Similar 
observations have been made in adrenal-insufficient dogs that were stressed, and in 
humans, heart rate, blood pressure and energy expenditure increase to the same extent 
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in glucocorticoid-deficient patients and control individuals who are exposed to a 
stressor-like high intensity exercise 133,134. Thus, the ability to develop an ASR in the 
absence of glucocorticoid hormones is conserved in rodents and humans.  
To test the hypothesis that hyperosteocalcinemia might explain the ability of ADX 
animals to develop an ASR, we used ADX Ocn+/- mice that have normal circulating 
bioactive osteocalcin levels (Figure 2.8H). When ADX Ocn+/- mice were exposed to 
stressors, the increase in energy expenditure, heart rate and blood oxygenation that 
was seen in stressed ADX WT mice was absent or markedly blunted (Figures 2.8I-L). 
ADX Ocn-/- mice also could not mount an ASR (Figures 2.8I-L). These results support 
the notion that, in the mouse, an increase in circulating bioactive osteocalcin levels is 
sufficient to trigger the development of an ASR. 
Further supporting the notion that increasing circulating bioactive osteocalcin 
levels is sufficient to trigger manifestations of an ASR, we observed that a single 
injection of exogenous osteocalcin significantly increased heart rate, energy expenditure 
and oxygen consumption in WT mice (Figures 2.8M-O). 
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Figure 2.8. High circulating osteocalcin levels account for the ability of 
adrenalectomized mice to develop an ASR 
Figure 2.8. High circulating osteocalcin levels account for the ability of adrenalectomized 
mice to develop an ASR. (A-E) Energy expenditure, oxygen consumption, temperature, heart 
rate and arterial oxygen saturation in ADX and sham-operated mice before and after foot shock. 
(F-G) Temperature and heart rate in ADX and sham-operated rats before and after restraint. (H) 
Serum Ocn levels in WT sham-operated, ADX, Ocn+/- ADX, Ocn+/- sham-operated and Ocn-/- 
ADX mice. (I-J) Energy expenditure and oxygen consumption in WT ADX, Ocn+/- ADX and 
Ocn-/- ADX mice before and after foot shock. (K-L) Heart rate and arterial oxygen saturation in 
WT ADX, Ocn+/- ADX and Ocn-/- ADX mice before and after foot shock. (M-O) Energy 
expenditure, oxygen consumption and heart rate in WT mice injected with Ocn (30 ng/g) or 
vehicle. (P) Schematic representation of the endocrine mediation of the ASR in bony 
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vertebrates. Stress signaling in the amygdala results in glutamate release in bone. Glutamate 
enters osteoblasts through Glast, exerts a possibly competitive inhibition on GGCX and as a 
result bioactive Ocn is released. Ocn binds to Gprc6a on peripheral parasympathetic neurons to 
inhibit their activity, allowing the ASR to begin (AP, action potential). Mice are 3-month-old 
females. Rats are 4-month-old females. Values are mean ±SEM. ns, not significant; *, p<.05; **, 











Figure S2.1. Related to Figure 1. Stressors trigger a rapid surge of circulating 
bioactive osteocalcin (Ocn) in rodents and humans 
Figure S2.1. Stressors trigger a rapid surge of circulating bioactive osteocalcin (Ocn) in 
rodents and humans. (A-B) FGF23 and sclerostin (SOST) circulating levels in TMT-exposed 
WT mice. (C) Bone Type (I) Collagen content in WT mice before and after TMT. (D) 
Immunofluorescence of basolateral amygdala (BLA) 3 weeks post injection of AAV8.2-hEF1α-
hM4Di-mCherry-WPRE. (E) Serum corticosterone levels before and after TMT exposure and 
after i.p. injection of CNO or vehicle into WT mice expressing hM4Di in the BLA. Mice are 3-
month-old females. Values are mean ±SEM. ns, not significant; *, p<.05; **, p<.01; by Student’s 
t-test or one-way ANOVA with bonferroni post hoc test. 
Fig. S1. Related to Figure 1. Stressors trigger a rapid surge of circulating bioactive osteocalcin (Ocn) 
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Figure S2.2 Related to Figure 2. Bioactive osteocalcin is released from cells of the 
osteoblast lineage during an acute stress response 
Figure S2.2. Bioactive osteocalcin is released from cells of the osteoblast lineage during 
an acute stress response. (A) Heart rate in nadolol- and vehicle-treated WT mice. (B) Serum 
corticosterone levels in ADX and sham-operated WT mice. (C-D) Expression of Ocn or Ggcx in 
WT tibia before and after TMT. (E) Serum Ocn levels and rate of Ocn release in alendronate- 
and vehicle-treated WT mice exposed to TMT. (F) Histomorphometric analysis of L4 vertebrae 
of alendronate- and vehicle-treated mice. (G) Serum CTX levels in WT mice before and after 
TMT. (H) Serum RankL levels in WT mice before and after TMT. (I) Bone RankL content in WT 
mice before and after TMT. (J) Supernatant Ocn levels after 1-hour treatment of osteoblasts 
with serum from unstressed and stressed Ocn-/- mice. (K) Supernatant Ocn levels after 1-hour 
treatment of osteoblasts with indicated hormones (n=12). Mice are 3-month-old females. Values 
are mean ±SEM. ns, not significant; *, p<.05; **, p<.01; by Student’s t-test or one-way ANOVA 
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Figure S2.3. Related to Figure 3. Glutamate mediates the stressor-induced release 
of bioactive osteocalcin from osteoblasts 
Figure S2.3. Glutamate mediates the stressor-induced release of bioactive osteocalcin 
from osteoblasts. (A) Immunofluorescence in femur metaphysis of pegylated diphtheria toxin 
(PEG-DT)- or vehicle-injected Vglut2iDTR mice (scale: 50 µm).  (B) Immunofluorescence of 
lumbar spinal cord (scale: 80 µm) for indicated markers in PEG-DT- or vehicle-injected 
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Vglut2iDTR mice.  (C) Serum CTX levels in PEG-DT- or vehicle injected Vglut2iDTR mice. (D-E) 
Immunofluorescence of WT femoral metaphysis (D) or dorsal root ganglia (DRG) (E) for Th 
(scale: 5 µm), IB4, CGRP, NF200, PAVLB (scale: 20 µm).  (F) Expression of Glast in indicated 
cell types. (G) Design of Glast-/- mice.  (H) Immunofluorescence of basolateral amygdala (BLA) 
3 weeks post injection of AAV8-hSyn-hM3Dq-mCherry-WPRE. (I) Serum Ocn levels before and 
after i.p. injection of D,L-(Tetrazol-5-yl)glycine (TZG) or vehicle into WT mice. Mice are 3-month-
old females. Values are mean ±SEM. ns, not significant; *, p<.05; **, p<.01; by Student’s t-test 
or one-way ANOVA with bonferroni post hoc test. 
 
 
Figure S2.4. Related to Figure 4. Osteocalcin signaling in peripheral organs is 
necessary to mount an ASR 
Figure S2.4. Osteocalcin signaling in peripheral organs is necessary to mount an ASR. 
(A) Serum hemoglobin levels in Ocn-/- and WT mice before and after foot shock. (B) Blood 
pressure in Ocn-/- and WT mice (n=6). (C-D) Energy expenditure and oxygen consumption in 
Gprc6a-/- and WT mice before and after foot shock. Mice are 3-month-old females. Values are 
mean ±SEM. ns, not significant; *, p<.05; **, p<.01; by Student’s t-test or one-way ANOVA with 































































































Figure S2.5. Related to Figure 5. Osteocalcin inhibits the parasympathetic tone to 
trigger an ASR 
Figure S2.5. Osteocalcin inhibits the parasympathetic tone to trigger an ASR. (A-B) 
Plasma norepinephrine (NE) levels and lung NE content in Ocn-/- and WT mice. (C-D) Urine 
Gprc6a-GFP
transgene
Gprc6a locus P2A eGFP hGH-PA
hGH-PA = human growth hormone poly A tail
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norepinephrine (NE) and Ucp1 expression in brown adipose tissue in Ocn-/- and WT mice 
(n=10). (E) Tyrosine hydroxylase (Th) content in heart of Ocn-/- and WT littermates. (F-G) 
Adra1a and Adra2b expression in trachea and heart of Ocn-/- and WT mice. (H) Phospho-
CREB content in heart of Ocn-/- and WT littermates. (I) Chat, Cht1 and Vacht1 expression in 
brain stem of Ocn-/- and WT mice. (J-K) Chat, Cht1 and Vacht1 expression in trachea and heart 
two hours after injection of Ocn or vehicle into WT mice. (L) Representative raw tracing of 
sympathetic nerve activity in WT mice before and after treatment with Ocn or Vehicle. (M-N) 
Serum gastrin levels in Ocn-/-, Gprc6a-/- and WT littermates. (O-P) Heart rate variability in Ocn-
/-, Gprc6a-/- and WT littermates. (Q) Contraction of mouse tracheal rings treated with increasing 
doses of acetylecholine without electrical stimulation and treated with either Ocn or vehicle. (R) 
Contraction of electrically stimulated Gprc6a-/- or WT mouse tracheal rings treated with atropine 
(10-6 M) or vehicle.  (S) Construct of Gprc6a-Gfp mice and Gfp status of founding litter (line 
founder in red). (T) Immunofluorescence of cardiac muscle (scale bar is 100 µm). (U) 
Endogenous tdTomato fluorescence of airway parasympathetic ganglia from Chat-tdTomato 
mice used for single cell electrophysiological recordings (scale bar is 8 µm). Mice are 3-month-
old females. Values are mean ±SEM. ns, not significant; *, p<.05; **, p<.01; by Student’s t-test 










Figure S2.6. Related to Figure 6. High circulating osteocalcin levels account for 
the ability of adrenalectomized mice to develop an ASR 
Figure S2.6. High circulating osteocalcin levels account for the ability of 
adrenalectomized mice to develop an ASR. (A) Serum Ocn levels in adrenalectomized (ADX) 
and sham-operated WT rats. (B) Blood glucose in ADX and Sham-operated mice before and 
after foot shock. Mice are 3-month-old females. Values are mean ±SEM. ns, not significant; *, 
p<.05; **, p<.01; by Student’s t-test or one-way ANOVA with bonferroni post hoc test.  
Fig. S6. R lated to Figur  6. High circulating osteocalcin levels account for the ability of adrenalectomized mice to 
















































Animal Models  
All animals of the same batch were born within an interval of 2 weeks and were kept in 
mixed genotype groups of 2-5 females in the same cage, at standard laboratory 
conditions (12 hr light/dark cycle, 22-25 °C, PicoLab Rodent Diet 5053 
and water ad libitum). For all experiments, we randomized mice into experimental 
groups and used females and littermates as controls unless otherwise stated. Ocn-/- 
(oscm1/oscm1) were previously described (Ducy et al., 1996), in brief, null alleles replace 
both the Bglap1 and Bglap2 genes. Gpr158-/- (Gpr158tm1.1(KOMP)Vlcg) mice were 
purchased from the KOMP repository (VG10108). This mouse line was made by the 
insertion of a LacZ cassette with a stop codon in the first two exons of Gpr158 135. 
Gprc6a-/- mice were described previously 70. Oc/oc mice, maintained on a C57BL/6J 
background, were obtained from Dr. Anne Villa and, in brief, contain a spontaneously 
occurring null mutation in Tcirg1. Tph1vilfl/fl maintained on a C57BL/6J background were 
described previously 109 and in brief are homozygous for floxed Tph1 alleles which are 
null when recombined as well as one allele of Vil-cre. Vglut2-cre mice maintained on a 
C57BL/6J background were obtained from Jackson Laboratory and were described 
previously 114 and in brief contain Cre knocked-in to the Vglut2 locus. iDTR mice, 
maintained on a C57BL/6J background, expressing a floxed stop cassette driving DTR 
in the Rosa26 locus, were obtained from Jackson Laboratories and were described 
previously 136. To generate the Gprc6a-gfp mouse line, maintained on a C57BL/6J 
background, P2A-EGFP-PolyA was inserted into the Gprc6a gene locus of BAC RP23 
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before the Gprc6a TGA stop codon using previously described recombineering methods 
137. The BAC transgene was then injected into pronuclei from B6CBAF2 mice. Mice 
were genotyped using primers: GFP forward 5'- GGTGAACCGCATCGAGC and GFP 
reverse 5'- GTCAGCAAACACAGTGCACA. To generate the Glast-/- mouse line, 
maintained on a C57BL/6J background, guide RNA sequences were selected flanking 
Exon 4 of the Glast gene using the MIT CRISPR Design Server. Two Guide RNAs 
flanking exon 4, TracrRNA (IDT) and Cas9 protein (IDT) were injected into C57BL/6N 
eggs to generate Glast null progeny. Deletion of exon 4 of the Glast gene was 
confirmed by sequencing and PCR genotyping. DTA mice were obtained from Dr. S. 
Kousteni 110 and in brief contain an Cre inducible DTA cassette. WT 129S6/SvEvTac 
mice were purchased from Taconic Biosciences and C57BL/6J from Jackson 
Laboratory. Upon arrival at the animal facility, mice were housed at least 2 weeks 
before performing experiments. Gpr158-/- mice were maintained on a 129-Sv/C57BL/6J 
mixed genetic background. Gprc6a-/- mice were maintained on a 129-Sv/C57BL/6J 
mixed genetic background. Ocn-/- mice were maintained on a 129-Sv background. Mice 
were housed five animals per cage (polycarbonate cages (35.5 × 18 × 12.5 cm)), under 
a 12 h light/dark cycle with ad libitum access to standard mouse chow and water prior to 
experimentation. All PCR oligonucleotides used for genotyping of any of the mice are 
available upon request. All experiments involving animals were approved by the 
Institutional Animal Care and Use Committee of Columbia University Medical Center. 
Human sample osteocalcin measurements 
The acute stress was carried out as previously described 94 under University of 
Pittsburgh IRFB -- #0307004. Consent was obtained and subjects of both sexes were 
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aged between 41-58 years and were in good health with no record of serious illness 
sample size was determined based on previously performed studies 94. In short, 
subjects engaged in a 10-minute evaluative speech task and blood was sampled 
before, immediately after and 30 minutes after the completion of the test. Circulating 
levels of bioactive osteocalcin in humans was estimated using a bioactive osteocalcin 
ratio according to a recently published method (Bonneau et al., 2017) that has greatly 
improved the accuracy of detecting undercarboxylated osteocalcin levels in human 
serum to within a 4.5-5.7% coefficient of variability. For human samples, separate 
ELISAs are used to measure total osteocalcin levels (ALPCO, 38-OSTHU-E01) and 
carboxylated osteocalcin levels (Takara Bio, MK111). Briefly, total and fully 
carboxylated osteocalcin levels were normalized to pre-stress levels and then 
undercarboxylated osteocalcin level was estimated for each participant by dividing 
Gla17-OCN by total-OCN. 
Cell Culture 
Mouse calvaria osteoblasts were isolated and cultured as described previously 47. In 
brief, calvaria of 2-5 day old mice of both sexes were dissected and digested in 
collagenase Type 2 (Worthington) and differentiated for 7-10 days in Alpha-MEM 
(Gibco), 5 mM beta-glycerophosphate (Sigma) and 100 ug/ml ascorbic acid (Sigma) at 




All animals of the same batch were born within an interval of 2 weeks and were kept in 
mixed genotype groups of 2-5 females in the same cage, at standard laboratory 
conditions (12 hr light/dark cycle, constant room temperature and humidity, and 
standard lab chow and water ad libitum). For each test, mice were transported a short 
distance from the holding mouse facility to the testing room in their home cages. Mouse 
weight was between 22g and 32g. Unless otherwise indicated, baseline blood was 
taken 48 hours prior to onset of stress. In the case of the time course experiment, each 
time point represents a separate batch of mice exposed to the indicated time period of 
stress. Stress was delivered by an experimentalist blind to the genotypes or treatment 
of the mice under study. For 2,3,5-Trimethyl-3-thiazoline (TMT) stress, food and water 
were removed immediately prior to TMT exposure. A cotton swab containing 10uL of 
TMT (Scotts Canada Ltd. 300000368) was placed in the home cage for 15 minutes. 
Serum was collected after 15 minutes of TMT exposure, and mice were transferred to a 
fresh home cage free of TMT odor. Exposure to rabbit urine (Kishel Scents, USA) was 
performed using the same procedure as that used for exposure to TMT. For foot shock 
stress, mice were placed in a conditioning apparatus (Med Associates, USA), which had 
a floor of stainless steel bars wired to a shock generator. They received 3 foot shocks (1 
sec, 1 mA), which were administered at time points of 60, 120 and 180 seconds after 
the animals were placed in the chamber. Blood was collected 15 minutes after onset of 
stress. For restraint stress, mice were placed in modified 50 mL Falcon tubes with holes 
allowing normal breathing. Blood was collected 45 minutes after onset of restraint 
stress. For rat experiments, 12-week-old female Sprague-dawley rats were exposed to 
restraint stress for 30 minutes.  
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In Vivo Treatments 
Mice were injected with nadalol intraperitoneally (i.p.) with either vehicle or 72 mg/kg of 
nadolol (Sigma, N1892) 30 minutes prior to onset of acute stress. Blood was taken from 
the submandibular vein of all mice 15 minutes after onset of stress.  
Mice were injected i.p. with either vehicle or 72 mg/kg of Alendronate sodium (Sigma, 
1012780) every other day for 14 days prior to onset of acute stress. Blood was taken 
from the submandibular vein of all mice 15 minutes after onset of stress. TMT stress 
was performed as described above. Vertebrae were then harvested for bone 
histomorphometric analysis.  
Mice were injected i.p. with either vehicle or .07 mg/g tamoxifen (Sigma, T5648) every 
day for 10 days. All experiments were performed between day 10 and day 20. TMT 
stress was performed as described above. Four hours after treatment, mice were 
sacrificed and organs were collected for gene expression.  
Control or VglutDTR Mice were injected i.p. with either vehicle or 8.3 ng/g PEG-DT (Ana 
Domingos) every day for 5 days. All experiments were performed between day 5 and 
day 8. TMT stress was performed as described above. 24 hours after final treatment, 
mice were sacrificed and organs were collected for histology.  
Mice were injected i.p. with either vehicle or 32 mg/kg of chlorisondamine (Sigma, 
C5366) 30 minutes prior to onset of acute stress. Blood was taken from the 
submandibular vein of all mice 15 minutes after onset of stress. TMT stress was 
performed as described above.   
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For measurement of Chat, Cht1 and Vcht1 expression in trachea and heart, WT mice 
were injected i.p. with either 30 ng/g or 100 ng/g of recombinant osteocalcin and 
returned to their home cage. Four hours after treatment, mice were sacrificed and 
organs were collected for gene expression.  
For the measurement of heat, VO2 and heart rate after osteocalcin injection, WT mice 
were injected i.p. with 10 ng/g of recombinant osteocalcin and heart rate was monitored 
for 5 minutes using the MouseOx (Starr Life Sciences) protocol described below.  
For measurement of circulating osteocalcin, WT mice were injected i.p. with .25 mg/kg 
of D,L-(Tetrazol-5-yl)glycine (TZG) and returned to their home cage. One hour after 
treatment, blood was collected from submandibular vessel. One mouse experienced a 
seizure and this mouse was excluded from the study.  
Bone Histomorphometry 
Bone histomorphometry analyses were performed on L3 and L4 vertebrae as described 
previously 138, in brief vertebrae were embedded in methyl methacrylate and sectioned. 
Von Kossa, Van Gieson, and toluidine blue staining were performed to measure 
mineralized bone volume over the total tissue volume (BV/TV) and osteoblast number 
per tissue area (N.Ob/T.Ar). 
Adrenalectomy 
In mice and rats a mid-dorsal skin incision was made at the level of the first through 
third lumbar vertebrae. The incision was moved laterally to expose the paracostal 
musculature. An incision was made just caudal to the 13th rib bilaterally. The adrenal 
gland on the left side was visualized by lateral retraction of the spleen. The adrenal 
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gland on the right side was visualized by cranial retraction of the liver. The adrenal 
gland and its associated fat pad were identified cranial and medial to the kidney and the 
vessels supplying the gland were crushed with two pairs of hemostats. Using blunt 
forceps, the entire fat pad was drawn out of the incision and the adrenal gland was 
removed intact. The muscle was sutured with absorbable suture bilaterally. The skin 
incisions were closed with wound clips. After surgery animals were provided with .9% 
saline for drinking water to supplement for loss of aldosterone. All experiments were 
performed after 10 days of post-operative rest. 
Energy Expenditure, Heart Rate, Heart Rate Variability, Lung Function, 
Temperature and Glucose Measurements 
Mice were acclimated for at least 12 hours prior to recording in energy expenditure 
cages (Oxymax-CLAMS, Columbus Instruments). From 12pm to 7pm the following day, 
the normal cage bottom was replaced with a modified shock grid floor and baseline 
readings were taken until 6pm. At 6 pm, five 1-second, 1mA shocks were applied over 
2.5 minutes. Data is represented as pre-shock and 1h post-shock. 
To measure heart rate and arterial oxygen saturation in mice, five days prior to 
experimentation a plastic sham collar (Starr Life Sciences) was placed on the mouse for 
5 minutes for acclimation. On the day of the experiment, the MouseOx Collar Sensor 
(Starr Life Sciences) was placed on a mouse that was then acclimated for 30 minutes in 
the conditioning apparatus (Med Associates, USA). After 15 minutes, 5 minutes of 
baseline parameters were recorded followed by five 1-second, 1mA shocks applied one 
per minute over 5 minutes. Heart rate and SpO2 at baseline and 5 minutes after the 
onset of stress are reported. To measure Newtonian airway resistance, blood pressure 
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and heart rate in mice, measurements of pulmonary mechanics were done as 
previously described 139 using the forced oscillation technique with a flexiVent (SCIREQ, 
CA). The mice were sedated with an i.p. injection of pentobarbital (50 mg/kg). A 
tracheostomy was performed with an 18 G cannula, and the mouse was connected to 
the flexiVent. EKG leads were placed on the extremities, and the right carotid artery was 
cannulated and connected to the blood pressure transducer connected to the flexiVent. 
The mice were ventilated at 150 Hz, tidal volume (VT) 10 ml/kg, and positive end-
expiratory pressure (PEEP) level of 3 cmH2O. To ensure identical volume history 
profiles, the lungs were first inflated to three times the VT and ventilated for 10 minutes. 
For vagotomy, mice were ventilated on the flexiVent and after 5 minutes of baseline 
recordings bilateral cervical vagotomy was performed. Heart rate variability is measured 
as the square root of the variance between NN intervals. For measurement of 
temperature, mice and rats were kept in their home cage and rectal temperature (Model 
BAT-12 Physitemp) was taken at -30 and -15 minutes. At 0 minutes mice were given 
foot shock stress as described above, then rectal temperature was measured again at 
15 minutes post stress. For rats, rectal temperature was taken at 0 minutes then again 
at 15 and 30 minutes after initiation of restraint stress.  
For measurement of blood glucose levels, mice were fasted for 4 hours and transported 
to the testing room at least one hour prior to the start of experimentation. Circulating 
glucose was measured using an Accu-Chek active blood glucose meter and 
corresponding test strips (Roche) on a drop of tail vein blood. Time 0 was collected 
immediately before foot shock stress. 
Immunohistochemistry and Histology 
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Immunofluorescence of lumbar spinal chord, femur, airway ganglia (trachea), cardiac 
ganglia, white adipose tissue and brain was performed on 16mm slices of frozen tissue 
fixed with 4% PFA in 0.1M sodium phosphate buffer, pH 7.4. Sections were 
permeabilized and blocked with 0.5% Triton in Tris buffered saline, pH 7.4 and 5% 
normal donkey serum. After blocking, sections were incubated with primary antibodies 
overnight at 4°C. For femur tissue, samples were decalcified for 24 hours in 0.5 M 
EDTA pH 7.4 according to previously described protocols 140. The following antibodies 
were used for this assay: anti-VGLUT2 (1:300) (Synaptic Systems, 135403), anti-
VGLUT2 (1:300) (Abcam, ab29157), anti-III Tubulin (1:500) (Abcam, 2G10), anti-GFP 
(1:300) (Abcam, ab13970), anti-Vacht1 (1:200) (Millipore, ABN100), anti-MCherry 
(1:300) (Abcam, ab167453), anti-OCN C-Terminal (1:300) (Karsenty lab), anti-TH 
(1:300) (Millipore, ab1542), anti-NF200 (1:300) (Millipore, ab5539), IB4  isolectin 
(Thermo Fisher Scientific, I23450), anti-PVALB (Swant, PVG-213), anti-PGP9.5 
(Millipore, ab5925), and anti-CGRP (Sigma, C8198). Sections were washed three times 
in Tris buffered saline, pH 7.4, followed by an incubation with secondary antibodies 
(Invitrogen, 1:200) diluted in blocking solution and were incubated 1h at RT. After three 
washes with Tris buffered saline, pH 7.4, sections were mounted with DAPI Fluoro-Gel 
(Electron Microscopy Sciences) and visualized using a Nikon Ti Eclipse microscope. 
When multiple experimental groups were present slides were blinded. Images were 
analyzed using ImageJ v2.0. Airway ganglia (trachea) of Chat-tdTomato mice were not 
fixed and instead mounted directly on a slide with Flouro-Gel and imaged and analyzed 
as described above.  
Gene Expression Analysis by qPCR 
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All dissections were performed under a Leica MZ8 dissecting light microscope. Adrenal 
weights were measured using a Mettler Toledo New Classic MS analytical scale. All 
organs were snap frozen in liquid nitrogen and kept at -80 ºC until use. Total RNA was 
isolated using TRIzol (Invitrogen). Total RNA was first incubated with DNAse I for 30 
minutes at room temperature to remove any genomic DNA. DNAse I-treated total RNA 
was converted to cDNA by using M-MLV reverse transcriptase (Thermo, 28025013) and 
random hexamers (Thermo, N8080127). qPCR was performed on a CFX96 Touch™ 
Real-Time PCR Detection System (Bio-Rad) and analyses were done using specific 
quantitative PCR primers and expressed relative to Hprt levels.   
Recombinant Osteocalcin 
Mouse uncarboxylated osteocalcin was purified from BL21 transformed with pGEX2TK-
mOCN as described 55,75. Briefly, GST-osteocalcin fusion protein was produced in BL21 
pLyS transformed with pGEX2TK-mOCN after induction with IPTG. Cells were collected 
in lysis buffer (PBS 1X, 10mM Tris pH 7.2, 2mM EDTA, 1% Triton and 1X protease and 
phosphatase inhibitor cocktail (Thermo, 78443). Following 4 freeze/thaw cycles and 
sonication, lysates were cleared by centrifugation. The supernatant was incubated with 
glutathione-sepharose 4B (GE, 17075601) for 4 hours at 4 ºC. Following 6 washes with 
washing buffer (PBS 1X, 1% Triton) and with PBS 1X, osteocalcin was then cleaved out 
from the GST moiety by using thrombin (GE, 27-0846-01). Four fractions were collected 
and each of them was incubated with Benzamidine sepharose (GE, 17-5123-10) for 30 
minutes at room temperature to remove thrombin. 
Immunoblotting 
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Frozen tissue were pulverized in lysis buffer (20 mM Tris-HCl (pH 7.65), 150 mM NaCl, 
1 mM EDTA, 1 mM EGTA, 1% Triton) supplemented with 1X protease and phosphatase 
inhibitor cocktail (Thermo, 78443). Lysates were clarified by centrifugation and protein 
concentration was determined by a Bradford assay. Clarified samples were heated at 
65 ºC in Laemmli buffer for 5 minutes. Proteins were run on an SDS-PAGE gel and 
transferred to nitrocellulose membrane (Bio-Rad, 1620112). Membranes were blocked 
with TBST-5% BSA for 1 hour, incubated with primary antibody overnight at 4 ºC and 
probed with HRP-conjugated antibodies for 1 hour at room temperature. The following 
antibodies were used in this study: anti-a-tubulin (1:5000, Sigma, T6199); anti-RankL 
(1:5000, Abcam, ab45039) and anti-Type-I-collagen (1:5000, Rockland 
Immunochemicals, 600-401-103-0.5), anti-TH (Cell Signaling, 2792), anti-Phospho-
CREB (Cell Signaling, 9198), anti-CREB (Cell Signaling Technology, 9104). Band 
intensities were quantified using ImageJ software. Dashed lines separating two bands 
indicate that these bands are on the same membrane but are not adjacent. 
Radiolabeled Glutamate Uptake 
Glutamate uptake was measured in osteoblasts after 10 days of culture. Cells were 
washed five times with basal buffer (135 mM NaCL, 3.8 mM KCl, 1.2 mM MgSO4, 1.3 
mM CaCl2, 1.2 mM KH2PO4, 10 mM glucose, 10 mM HEPES) and then incubated with 1 
µM 3H glutamate (PerkinElmer, NET490001MC), lysed and measured on a scintillation 
counter. µM of glutamate estimated from CPU count based on standard curve of pure 
µM of serially diluted 3H glutamate. 
Measurement of Circulating Factors 
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For either mice or rats, blood was collected from the facial vein into Capiject (Terumo, 
TM) tubes followed by centrifugation at 15 X g for 10 minutes. All serum aliquots were 
stored at -80 ºC until use. Circulating levels of osteocalcin in mouse or rat serum were 
determined with a specific ELISA previously described (Ferron et al., 2010a; Ferron et 
al., 2010b). Total levels of osteocalcin and carboxylated osteocalcin were estimated 
using two different specific antibodies. Bioactive osteocalcin was determined by 
subtracting the carboxylated osteocalcin levels from total osteocalcin levels (Ferron et 
al., 2010a; Ferron et al., 2010b). Rate of osteocalcin release was determined by 
calculating the difference in serum bioactive osteocalcin and dividing by the time 
elapsed since the onset of stress. CTX (IDS, AC-06F1), PiNP (IDS, AC-33F1), gastrin 
(Sigma, RAB0200), glutamate (Abcam, ab83389), sclerostin (R&D, MSST00), 
epinephrine (Abnova, KA1882), norepinephrine (Abnova, KA1891), corticosterone 
(abcam, ab108821), aldosterone (ab136933), cortisol (ab108665) and Fgf23 (Kainos, 
CY-4000) were measured according to manufacturer’s instructions. NE detection in 
organs was performed by HPLC as previously described 139. Hemoglobin and 
Potassium was measured using Element POC (EPOC) rapid blood analyzer (Heska) 
according to manufacturer's instructions.  
In Vitro Procedures 
For treatment of osteoblasts, on day 10 of culture, cells were incubated in serum-free 
media without glutamate for four hours before addition of treatment. In cells that 
received warfarin pre-treatment,10 µM of warfarin (Santa Cruz, 129066) was added to 
the media on days 8 and 9 of culture, then glutamate treatment was performed on day 
10. In all groups, supernatant was collected without disturbing cells an hour after onset 
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of treatments on day 10. Treatments included pituitary extract (Thermo Fisher Scientific, 
13028014), growth hormone (BioVision, 4770), ACTH (Phoenix Pharmaceuticals, 001-
21), TSH (Sigma, T8193), LH (Sigma, L5269), FSH (Sigma, F2293), prolactin (Sigma, 
SRP4688), MSH (Sigma, M4135), PTH (Sigma, P3921), leptin (Sigma, L3772), insulin 
(Sigma, I3536), glucagon (Sigma, G2044), dexamethasone (Sigma, D4902), 
isoproterenol (Sigma, 1351005), orexin A (Phoenix Pharmaceuticals, 003-30), NPY 
(Bachem, H-6375), dopamine (Sigma, H8502), substance P (Sigma, S6883), CGRP 
(Phoenix Pharmaceuticals, 15-09), BDNF (PeproTech, 450-02), glutamate (Sigma, 
49621) and UCPH-102 (Abcam, 146404). The gamma-carboxylase (GGCX) enzymatic 
activity assay was performed on recombinant OCN as previously described 141. 
Tracheal Ring Electrophysiology 
Organ bath experiments were performed as previously described 139. In brief, 10-week-
old male mice tracheal rings were excised and immersed in Kreb-Henseleit (KH) buffer 
(in mM: 115 NaCl, 2.5 KCl, 1.19 CaCl2, 2.46 MgSO4, 1.38 NaH2PO4, and 5.6 glucose, 
pH 7.4). The tracheal rings were suspended at 0.5 g resting tension in oxygenated KH 
buffer at 37 ºC on a tissue bath system. The rings were at 0.5 g isotonic force with the 
following electrical field stimulation: Train: 0.013 Trains/s, Train duration: 5 s, Pulse 
duration: 0.5 ms, Volts: 24 V, Stimulation rate: 20 Hz. Electrical stimulation was applied 
using Acqknowledge software from BIOPAC Systems. Trachea rings were treated with 
either 10-6 M atropine (Sigma, A0132) or 10 ng/ml recombinant osteocalcin. Values 
reported are post-treatment magnitude (in force) of electric field-stimulated contraction 
normalized by pretreatment contractions.  
Electrophysiology 
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The preparation of trachea parasympathetic postganglionic neurons was performed as 
described with modifications 142. Briefly, mice on C57B6 genetic background (male and 
female, 3-4 weeks old) were anesthetized with isoflurane and then sacrificed with 
cervical dislocation. Then intrathoracic trachea and mainstem bronchi with the vagus 
nerves attached were removed and dissected in ACSF (bubbled with 95% O2/5% CO2) 
containing (in mM): NaCl 124, KCl 3, CaCl2 2, MgCl2 2, NaH2PO4 1.23, NaHCO3 26, 
glucose 10, pH 7.4 with NaOH. The airways were cut ventrally along the midline, 
opened as a sheet, and pinned, lumen-side down, to a Sylgard-lined Petri dish. After 
excess connective tissue and fat were cleared, the trachea was treated with a 
combination of collagenase (2mg/ml) and dispase (1mg/ml) prepared with modified 
ACSF without Mg2+ and Ca2+ for 30 minutes at 37 ºC. The tracheal tissue was then 
transferred to a recording chamber and constantly perfused with bath solution (33 ºC) at 
2 ml/min for electrophysiological recording. Extracellular recordings were made from 
identified trachea parasympathetic postganglionic neurons with a glass electrode filled 
with ACSF (resistance=2-5 MΩ) with a multiclamp 700A amplifier (Molecular Devices). 
A loose seal was formed (resistance= 10-20 MΩ) when the micropipette touched the 
surface of a neuron. For experiments involving treatment with sera, WT and Ocn-/- mice 
were exposed to TMT for 15 minutes and blood was collected as described above. Sera 
from each experimental group were pooled and aliquoted. After 5-10 minutes of 
baseline response was recorded, drugs were applied to the recording chamber through 
bath application.  
In Vivo Neural Recordings of Sympathetic and Parasympathetic Nerve Activity 
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Each mouse was anesthetized with intraperitoneal administration of ketamine (91 mg/kg 
body weight) and xylazine (9.1 mg/kg body weight). Tracheotomy was performed by 
using PE-50 tubing to provide an unimpeded airway for the mouse to spontaneously 
breathe O2-enriched room air. Next, a micro-renathane tubing (Braintree Scientific, 
MRE-40) was inserted into the right jugular vein for infusion of the sustaining anesthetic 
agent (α-chloralose: initial dose of 12 mg/kg, then sustaining dose of 6 mg/kg/h). A 
second MRE-40 catheter was inserted into the left common carotid artery attached to a 
pressure transducer (iWorx Systems, Inc., BP-100) for continuous measurement of 
arterial pressure and heart rate. Core body temperature was monitored through a rectal 
probe and maintained at 37.5 ºC throughout the experiment. Next each mouse was 
instrumented for sympathetic or parasympathetic nerve recording. 
To gain access to the nerve fascicle that innervates the left kidney, a peroneal incision 
was performed along the left flank between the ilium crest and thoracic ribs. The renal 
nerve was isolated and placed on a bipolar platinum-iridium electrode (A-M Systems, 
36-gauge) and secured with silicone gel (WPI, Kwik-Sil). The electrode was attached to 
a high-impedance probe (Grass Instruments, HIP-511) and the nerve signal was filtered 
at a 100- and 1000-Hz cutoff with a Grass P5 AC pre-amplifier and amplified 105 times. 
The nerve signal was then routed to a speaker system and to an oscilloscope (Hewlett-
Packard, model 54501A) to monitor the audio and visual quality of the nerve recording. 
The nerve signal was also directed to a resetting voltage integrator (University of Iowa 
Bioengineering, model B600c) and finally to a MacLab analog-digital converter 
(ADInstruments, Castle Hill, New South Wales, Australia, Model 8S) containing software 
(MacLab Chart Pro; Version 7.0) that utilizes a cursor to analyze the total activity 
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(integrated voltage) and to count the number of spikes/second that exceed the 
background noise threshold. Under stable plane of anesthesia and strict isothermal 
conditions (37.5 ºC), continuous recording of baseline sympathetic activity was 
measured over a 10-minute control period. Vehicle or osteocalcin was then slowly 
administered, and the sympathetic response recorded continuously for the next 120 
minutes. To test the responsiveness of the preparation, an intravenous infusion of 
sodium nitroprusside (20 µg) was administered. The reflex change in sympathetic nerve 
activity was tabulated at the exact time that peak decrease in arterial pressure occurred. 
To access the hepatic parasympathetic vagal nerve the mouse was placed in a dorsal 
position. An incision was made in the abdominal region below the rib cage to access a 
chain of the hepatic parasympathetic nerve located on the right lateral side of the 
esophagus. The hepatic vagal nerve fascicle was carefully isolated from its surrounding 
connective tissues and attached to a bipolar platinum-iridium electrode. The nerve 
signal was filtered, amplified and quantified as above. Under stable plane of anesthesia 
and isothermal conditions (37.5 ºC), a continuous recording of basal hepatic vagal 
nerve activity was measured over a 10-minute control period before vehicle or 
osteocalcin was slowly administered. The response of hepatic vagal nerve activity 
recorded continuously for the next 120 minutes.  
A separate cohort of Ocn-/- and wild type control and female mice were prepared as 
above for direct hepatic vagal nerve activity recording without the tracheotomy. These 
mice were able to spontaneously breathe O2-enriched room air unimpeded through their 
own nasal passages. With a stable plane of anesthesia and under strict isothermal 
conditions (37.5 ºC), continuous recording of basal hepatic vagal nerve activity was 
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measured for a 30-minute control period. A small cotton swab soaked with 2,5-dihyro-
2,4,5-trimethylthiazoline (TMT) was then placed at the end of the mouse’s nose. The 
effects of TMT on hepatic vagal nerve activity was recorded for the next 60 minutes. 
The TMT-soaked cotton swab was removed, and the study extended for an additional 
30 minutes for a recovery period.    
At the conclusion of each study, mice were sacrificed using an overdose of 
ketamine/xylazine, the hepatic or renal nerve fiber was severed, and the residual 
background noise was used to normalize the basal nerve activity. Separate mice were 
used for each nerve recording. 
Stereotaxic Injection 
Stereotaxic surgery was performed in 3-month-old C57BL/6J male mice obtained from 
the Jackson Laboratory. Mice were anesthetized with i.p. injection of a mixture of 
ketamine hydrochloride (100mg/kg of BW - 1000 Virbac) and 100 mg/ml BW xylazine 
(10mg/kg of BW - Rompun 2%; Bayer) and placed in a stereotaxic frame (900SL-
KOPF). Ophthalmic eye ointment was applied to the cornea to prevent desiccation 
during surgery. The fur in the area surrounding the incision was trimmed and Vetedine 
solution (Vetoquinol) was applied. 1 µL of 1.4X10^9 vg/µL AAV8.2-hEF1α-hM4Di-
mCherry-WPRE (MIT Viral gene Transfer Core) was injected at 100 nL per minute. 1 µL 
of 2.0X10^9 vg/µL AAV8-hSyn-hM3Dq-mCherry-WPRE (Addgene) was injected at 100 
nL per minute. The viruses were injected bilaterally into the basolateral amygdala ((from 
bregma) AP = -.82 mm, DV = +/-2.80 mm and ML = -5.00 mm) using a 1 µL Hamilton 
syringe (65458-01). To limit reflux along the injection track, the needle was maintained 
in place for 10 minute before and after each 1 µL injection. Then, the skin was closed 
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using silk suture and the mice were injected locally with surgical analgesic. Three weeks 
after injections baseline blood was taken. Two days later mice were injected with 5.0 
mg/kg clozapine-N-oxide (CNO) (Sigma, C0832). In the case of hM4Di-expressing 
mice, CNO was injected one hour prior to acute TMT stress. Then blood was taken 15 
minutes after onset of TMT. In the case of hM3Dq-expressing mice, CNO was injected 
20 minutes prior to blood collection. Expression of hM4Di-mCherry or hM4Dq-mCherry 
in the BLA was confirmed in every mouse by post-hoc immunofluorescent histological 
analysis.  
Isolation of Total RNA and Northern Blot Analysis 
Total RNA was isolated from different tissues by the TRIzol method. Briefly, mice were 
exposed to no shock (-) or foot shock (+) and 1 hour later tissues were collected and 
processed for RNA isolation by TRIzol method according to manufacturer’s instructions 
(Sigma). Seven micrograms of total RNA from each sample were then electrophoresed 
in a 1% agarose gel containing MOPS (0.02M), sodium acetate (0.005M), EDTA 
(0.001M), and 5.4% formaldehyde. The RNA was then transferred to Hybond N+ 
membrane (Amersham Biosciences) in 10× SSC (1.5M sodium chloride and 
0.15M sodium citrate) using capillary blotting overnight. The blot was cross-linked and 
prehybridized at 60 ºC in hybridization buffer (0.33M sodium phosphate and 
6.66% SDS). The blot was then hybridized at 60 ºC for 12 hours with Ocn cDNA probe 
radiolabelled by random primer labeling with alpha32PdCTP (6,000 Ci/mmol). The 
blot was washed (2 times, 45 minutes each) at 60 ºC in 0.2X SSC with 0.1% SDS 
and autoradiographed with Kodak Biomax MR film at −80 ºC with an intensifying screen 
for varying duration. 
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Data Analysis 
All values are depicted as mean ± SEM. Statistical parameters including the exact value 
of n, post hoc test and statistical significance are reported in every figure and figure 
legend. Numbers of mice were estimated to be sufficient based on pilot experiment and 
previously published work 55,70,75. Outlier tests or tests for normality were not performed. 
Data are estimated to be statistically significant when p≤0.05 by Student’s t-test One-
way ANOVA or Two-way ANOVA. In every figure an asterisk denotes statistical 




CHAPTER 3: DISCUSSION 
 
I will try here to highlight what I see as the significance of this work and some of 
the new questions it raises. The three main areas I will review are the glutamatergic 
system of bone, the endocrine control of the parasympathetic tone by the skeleton, and 
the crosstalk between bone and the adrenal gland. Before delving into these particulars, 
I would propose that in more general terms this works suggests a new way of thinking 
about bone. By showing that osteocalcin is a stress hormone, i.e., a hormone reactive 
to stress and contributing to it, this work suggests that osteocalcin and therefore bones 
enable survival in the face of acute danger. Moving forward, as we search for new 
functions of osteocalcin and perhaps, entirely new functions of bone, it may be fruitful to 
think and hypothesize in terms of this physiology of danger.  
I. The glutamatergic system of bone 
 
For centuries, anatomists and histologists have observed neuronal processes 
within bone. In 2002, the first known function of a neuron within bone was described: 
adrenergic processes located within bone increase bone remodeling by activating the 
adrenergic receptor Adrb2 on osteoblasts29. Here, we describe what we believe is the 
second known function of a neuron of bone. We identified a population of glutamatergic 
neuronal processes within bone that are required for the release of osteocalcin during 
an ASR (Figure 3.1). This population of neurites expresses Vglut2 but not any markers 
of noradrenergic or sensory neurons. These neurites also exhibit an anatomical pattern 
that is distinct from both adrenergic neurites, which track blood vessels in bone, and 
sensory neurites, which are concentrated in the periosteum143. Despite these distinct 
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qualities, there are many questions that must be answered before we can safely 
conclude that these are an entirely novel population of neurites. First, what peripheral 
ganglia do they come from? Taking the femur as an example there are two reasonable 
possibilities, the dorsal root ganglia or the sacral sympathetic chain ganglia. Cre-
dependent Viral retrograde tracing technologies, such as retro AAV or Cre-dependent 
pseudorabies virus, may reveal which peripheral ganglia are the source of the 
glutamatergic neurites in bone144. Second, what types of neurons are the glutamatergic 
neurites of bone a part of? Once the location of the neurons will be determined, 
transcriptional profiling and lineage tracing might reveal whether they are a subtype of 
sympathetic or sensory neuron or something else altogether. Further, does this 
glutamatergic neuronal population enervate the skeleton alone or does it enervate other 
organs as well? What regions of the brain form second- or third-degree connections 
with the glutamatergic neurites of bone? Are these neurons uniquely activated by the 
ASR or also by other cues? Finally, what would functional studies using chemogenetic 
or optogenetic stimulation of the glutamatergic neurons that enervate bone reveal about 
the functions of these peripheral neurons both within bone and outside of it? I believe 
addressing these questions will provide a better understanding of the identity and 
purpose of a population of neurites within bone characterized here.  
 The glutamatergic pathway described in this thesis also represents a fully new 
mechanism of action for glutamate. Like Zelig, the human chameleon, conforming 
equally well in the Third Reich as in a minyan of rabbis, glutamate is a single molecular 
entity with many and varied identities. Glutamate, though a simple structure, employs 
multiple unrelated biochemical mechanisms to affect physiology that I will briefly review 
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here. First and foremost glutamate is an amino acid. It is important to the coiled 
structure of many α-helices to the extent that, on average, it is the most abundant 
constituent of α-helices and the least abundant constituent of β-sheets145. Glutamate is 
the only amino acid that can be carboxylated, as has been described in detail above. In 
addition to its role as an amino acid, glutamate has unrelated functions as both a 
catabolite and an anabolite. As a catabolite, glutamate is a major source of energy by 
feeding directly into the TCA cycle and enabling the formation of ATP146. As an 
anabolite, glutamate is required for the formation of glutathione, one of the main 
physiological antioxidants. This function explains why a genetic deficiency in the 
transformation of glutamate to glutathione causes oxidative stress-induced anemia in 
humans147. Glutamate is also the most abundant excitatory neurotransmitter in the 
brain. In glutamatergic synapses throughout the brain, glutamate is released from the 
presynaptic terminal and signals on the postsynaptic neuron through either ionotropic or 
metabotropic glutamate receptors148. It regulates a vast array of physiological processes 
in the brain that are too abundant to list fully here but include learning and memory 
formation. Finally, glutamate is the molecule responsible for one of the five principal 
tastes, umami, by signaling through yet a different receptor complex on the tongue149.  
 I have described in this work a new biochemical function for glutamate as a 
physiological inhibitor of GGCX activity. By inhibiting GGCX, glutamate impedes its 
ability to post-translationally modify (carboxylate) and thus deactivate osteocalcin. To 
our knowledge this represents the first time that glutamate is identified as a 
neurotransmitter outside the brain and shown to affect a target tissue by acting as a 
inhibitor of a regulatory enzymatic reaction. That glutamate is a substrate if the GGCX 
81	  
suggests that it may engage in competitive inhibition and this possibility can be 
determined through future biochemical analyses of the interaction. The ability of 
glutamate to inhibit GGCX does not eliminate the possibility that glutamate might act on 
osteoblasts in other ways as well, ways that I have not yet addressed experimentally. It 
will be important to determine whether glutamate’s other professions, as an amino acid, 
TCA substrate, glutathione precursor, or ligand of ionotropic and metabotropic 
glutamate receptors might also regulate the endocrine or any other functions of bone. 
Fortunately, there are many genetic tools that can be used to study the roles of each of 
these in osteoblasts in the regulation of osteocalcin, in the execution of the ASR in bony 
vertebrates and in the control of bone mass. 
	  
Figure 3.1. A working model of the control of osteocalcin by glutamate 
Figure 3.1. A working model of the control of osteocalcin by glutamate. Following acute 
stress osteocalcin is released into general circulation. This requires peripheral Vglut2+ cells and 
a glutamate transporter, Glast. A distinct population of glutamatergic neurites are abundant in 
metaphyseal bone. Glutamate transport into osteoblasts inhibits the activity of γ-glutamyl 












Regardless of what glutamate might do to the osteoblast, the fact that glutamate 
transport regulates carboxylic status has implications both for osteocalcin biology and 
beyond. For osteocalcin, this implies that increasing glutamate transport into 
osteoblasts could increase uncarboxylated osteocalcin levels in the blood stream and 
thereby achieve the effects of high osteocalcin levels. For example, a mouse model 
over-expressing Glast specifically in osteoblasts might have better glycemic control, 
enhanced cognition or improved exercise capacity. Such a mouse model is currently in 
development. In the future, pharmacologically increasing glutamate transport into 
osteoblasts may be a way of treating diseases caused in part by decreasing circulating 
osteocalcin.  
 Beyond bone, this work suggests the possibility that in other cell types glutamate 
transport might determine carboxylic status of proteins. To take one important example, 
in hepatocytes of the liver, carboxylation of coagulation proteins like Factor X is required 
for their ability to clot blood52. Warfarin, an inhibitor of carboxylation, is the most 
commonly used anticoagulant drug52. Is glutamate a natural regulator of carboxylation 
of the coagulatory proteins in the liver? If so, what is the extracellular source of 
glutamate for hepatocytes of the liver? Regardless of what happens naturally, could 
manipulation of glutamate transport into hepatocytes be a therapeutically useful method 
of anticoagulation? These are just an example of some of the physiological and 
therapeutic questions that arise from the finding that glutamate is a regulator of 
carboxylation.  
II. Endocrine control of the parasympathetic tone by the skeleton 
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 The next finding I would like to discuss is the inhibition of the 
parasympathetic activity by osteocalcin. One noteworthy piece of data included in this 
thesis work is the one collected through direct microelectrode nerve recordings of 
parasympathetic nerve bundles in the liver. Using this technique we showed that 
injection of osteocalcin decreases parasympathetic activity within minutes. Further, an 
acute stressor decreases parasympathetic activity within minutes in WT but not Ocn-/- 
mice. Although intuitively it makes sense that the parasympathetic “rest and digest” 
system would be “turned off” during an ASR this has never been shown before to be the 
case. To the best of our knowledge, osteocalcin signaling is the first known mechanism 
that explains how this occurs in vivo. This does not exclude the possibility that other 
mechanisms might exist; on the contrary, it provides an exciting incentive to identify 
them, if they do.  
 There are still many unanswered questions surrounding the role of osteocalcin in 
parasympathetic activity. Tracheal explants and single cell recordings of isolated 
parasympathetic tracheal ganglia suggests that osteocalcin acts on local 
parasympathetic neurons in a Gprc6a-dependent manner. However, there is still some 
ambivalence regarding where exactly osteocalcin acts to control parasympathetic 
activity. Our ability to answer this question is limited for now by the absence of 
established Cre driver mouse model that could delete Gprc6a specifically in peripheral 
parasympathetic ganglia. A reliable mouse model expressing Cre under the control of 
the Chat promoter did not exist until very recently and in any case would delete Gprc6a 
in all cholinergic neurons, including those in pre-ganglion parasympathetic neurons of 
the brainstem, as well cholinergic neurons in other areas of the central nervous system. 
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Nevertheless, this model is currently being generated. A mouse model expressing Cre 
under the control of the Sox10 promoter might provide a better way to delete Gprc6a in 
postganglionic but not preganglionic parasympathetic neurons. The significant caveat is 
that Sox10 is also expressed during development by any other peripheral cell type 
derived from the neural crest, including those in the sympathetic nervous system. 
Together, these models and any future models that more directly target postganglionic 
parasympathetic cells may provide the first answers as to whether osteocalcin acts 
directly in postganglionic parasympathetic neurons in order to inhibit parasympathetic 
activity.  
 The second unanswered question regarding the regulation of the 
parasympathetic tone by osteocalcin is how signaling on Gprc6a is capable of inhibiting 
the firing rate of parasympathetic neurons in a few minutes. What ion channels and 
second messenger pathways are being recruited by osteocalcin through Gprc6a in 
order to achieve this outcome?  
 The third and final question regarding the parasympathetic tone and osteocalcin 
is more general. To the best of our knowledge, this is the first time a hormone has been 
shown to have a physiological effect on parasympathetic activity at the postganglionic 
level of the neuronal relay. Instead of signaling in the dorsal motor nucleus of the vagus 
nerve or elsewhere in the brain, osteocalcin fine-tunes the directives given to the 
autonomic nervous system by signaling peripherally. By analogy, instead of pure 
authoritarianism, parasympathetic activity is governed by both central and peripheral 
signals, a kind of federalism. Might there be other such peripheral signals? Are any 
other hormonal receptors functional in postganglionic parasympathetic neurons? Are 
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the same hormonal receptor expressed by postganglionic parasympathetic neurons in 
different target organs or are there different ones in each target organ? Is there an 
endocrine control of the parasympathetic nervous system that modulates the signals 
arising from the central nervous system? 
III. The crosstalk between bone and the adrenal gland 
 
 The third and final finding in this work I will discuss here is the newfound 
relationship between bone and the adrenal gland. Here there are more open and 
fundamental questions and new directions than in any of the other aspects of this work. 
Steroid hormone synthesis (steroidogenesis) in the adrenal is thought to be controlled 
nearly exclusively, by the hypothalamus-pituitary-adrenal (HPA) axis, the renin-
angiotensin system (RAS) and potassium.  
 
	  




































Figure 3.2. A working model of contribution of osteocalcin to the acute stress response 
(ASR). Osteocalcin is release within minutes during acute stress in glutamate dependent 
manner from osteoblasts. Osteocalcin decreases the parasympathetic nervous system and is 
thus required for the unfolding of the ASR. The hypothalamic-pituitary-adrenal axis, the classical 
ASR endocrine response is in crosstalk with osteocalcin. Osteocalcin favors the release of 
corticosterone and the development of the adrenal in utero. Corticosterone is a powerful 
inhibitor of osteocalcin and when the adrenal glands are missing the relief of this negative 
inhibition increase osteocalcin levels and allows the ASR to proceed normally.  
 
Here we describe a new axis between bone and adrenal, consisting of osteocalcin that 
is required for normal steroidogenesis in the adrenal (Figure 3.2). In primates, and 
rodents, exogenous osteocalcin stimulates the release of both cortisol/corticosterone 
and aldosterone. And when osteocalcin is missing from both the mother and the 
progeny there is a severe adrenal insufficiency. In such mice corticosterone is also low 
during the ASR, which means that ACTH release from the pituitary during stress is 
unable to compensate for the lack of osteocalcin. Considering that bone, through 
osteocalcin, is also required for steriodogenesis in the testes, this indicates that bone is 
the only organ outside the pituitary to exert endocrine control over multiple (more 
precisely, three) steroid hormones’ biosynthesis. Innumerable questions remain. What 
is remarkable is that unlike what is the case for the pituitary gland that uses many 
hormones for this purpose bone utilizes only one, osteocalcin.  
 Does osteocalcin signal in the brain or directly in the steroidogenic cells of 
the adrenal gland to regulate corticosterone/cortisol and aldosterone synthesis? 
Assuming the latter, what intracellular molecular mechanisms does osteocalcin use to 
regulate steroidogenesis and how do they compare to those used by ACTH? What 
osteocalcin receptor is required for osteocalcin to regulate corticosterone? Are the same 
or different signaling pathways responsible for both the acute stimulation of 
corticosterone and aldosterone release and the size of the adrenal gland? Finally, the 
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defect in steroidgenesis, though substantial, is only detectable in Ocn-/- mice derived 
from Ocn-/- mothers and not those born from Ocn+/- parents. This provokes two 
questions. First, is corticosterone or aldosterone release ever impaired under any 
circumstance in Ocn-/- mice from Ocn+/- mothers, for example at a specific time point 
after stress, with specific stressors? Or are Ocn-/- mice from Ocn+/- mothers completely 
normal in every context in terms of their adrenal gland function? Second, how does 
having an Ocn-/- mother produce a defect in the adrenal gland of the offspring? There 
are some clues that may help answer this question. Ocn-/- mice derived from Ocn-/- 
parents also have a more severe defect in learning and memory than Ocn-/- mice from 
Ocn+/- parents74. This is because maternal osteocalcin crosses the placenta and 
signals in the brain of the embryo. Is the same true of the adrenal gland? How does 
osteocalcin signaling favor the development of the adrenal gland? How does it impact 
adrenal steroidogenesis post-natally? 
 Corticosterone signaling in the pituitary is a powerful down-regulator of ACTH, 
the hormone that favors its synthesis. The exact same thing is true in bone. 
Corticosterone signaling is, perhaps, the most powerful known down-regulator of 
osteocalcin131. This is a phenomenon that has been known for over 30 years. This 
observation appears now less puzzling in the context of osteocalcin’s endocrine role in 
the adrenal gland. Moreover, we show here, for the first time, that the inhibition of 
osteocalcin by corticosterone is functionally relevant. Following adrenalectomy, the 
inhibition by corticosterone abates and osteocalcin levels increase, which enables a 
normal ASR to proceed despite the absence of the adrenal stress hormones, 
epinephrine and corticosterone (Figure 3.2). Of course adrenalectomy is a severe 
88	  
scenario that is seldomly recapitulated in nature outside of rare diseases where the 
HPA axis is defective. Is this inhibition of osteocalcin more generally relevant in 
physiology?  
Just as in, for example, the immune system, turning off the ASR is just as 
important as turning it on. As such, the immune system has evolved a myriad of 
mechanisms to temper and terminate an acute inflammatory response. Might the 
endocrine relationship between bone and the adrenal be one way in which the ASR is 
tempered or terminated? There is a saying, “Fear is like fire, it can warm you in winter or 
it can burn your house down.” Might a negative feedback loop between bone and the 
adrenal gland prevent the deleterious effect that a too long ASR would necessarily 
have? Again, this provokes many other questions. Would deleting the corticosterone 
receptor, Nr3c1, specifically in osteoblasts lead to a mouse that is a model of 
osteocalcin gain of function? Would the ASR be pathologically extreme or long when 
Nr3c1 is specifically deleted in osteoblasts? Moreover, might glucocorticoid signaling 
through Nr3c1 in osteoblasts explain some of the phenotypic differences between the 
acute stress response and the chronic stress response88,150,151? Addressing these 
questions experimentally is ongoing and will be crucial to understanding the functional 
importance of the crosstalk between bone and the adrenal gland.  
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